Wayne State University
Wayne State University Dissertations

1-1-2013

Acidic Pericellular Ph: Effects On Proteolysis And
Gene Expression As Determined In 3d Models Of
Breast Carcinoma
Jennifer M. Rothberg
Wayne State University,

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations
Recommended Citation
Rothberg, Jennifer M., "Acidic Pericellular Ph: Effects On Proteolysis And Gene Expression As Determined In 3d Models Of Breast
Carcinoma" (2013). Wayne State University Dissertations. Paper 694.

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.

ACIDIC PERICELLULAR PH: EFFECTS ON PROTEOLYSIS AND GENE
EXPRESSION AS DETERMINED IN 3D MODELS OF BREAST CARCINOMA
by
JENNIFER M. ROTHBERG
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR of PHILOSOPHY
2013
MAJOR: CANCER BIOLOGY
Approved by:
___________________________________
Advisor

Date

___________________________________
___________________________________
___________________________________
___________________________________
	
  

© COPYRGHT BY
Jennifer M. Rothberg
2013
All Rights Reserved

DEDICATION
I dedicate this dissertation to my wonderful family. Particularly to my patient
husband, Mike, who has helped and encouraged me throughout the many years
of research. He and our daughters, Audrey and Morgan, have been endlessly
flexible and understanding. A huge debt of gratitude goes to my parents who
have unselfishly sacrificed so much to make this process easier on me, while
making it fun for my girls.

	
  

ii	
  

ACKNOWLEDGEMENTS
Foremost, thank you to Bonnie for being a wonderful mentor.

I have truly

enjoyed learning from you, not only as a scientist, but also you provided for me a role
model as a consummate professional. You have shown me every aspect of what it
takes to be a successful scientist. You have guided me all along and allowed me to gain
experience in fostering collaborations and forming collegial friendships by attending both
international and student centered meetings. I will do my best to emulate you as I move
on in my career.
I am thankful to all the members of the Sloane laboratory past and present. Of
special note are both Mansoureh (Sue) Sameni and Arulselvi (Selvi) Anbalagan who
have helped to make my laboratory experience a success. Sue advised on many of the
protocols and Selvi has been a tremendous help with tissue culture and so much more.
I also owe a note of appreciation to the microscopy core staff Kami Moin, Mary Olive,
and Charlie Harkins who have remained endlessly patient with me and facilitated the
imaging that I am so proud of.
I would like to thank all my collaborators who have allowed me to use their tools
and expertise.

In particular, Dr. Gillies and his laboratory who have been very

supportive and I greatly appreciate all our interactions that put together some great
manuscripts. A special thank you to Gillies laboratory members Jonathan Wojtkowiak
and Kate Bailey who provided the in vivo data and have been amazing colleagues.
I am grateful for the cancer biology program and graduate school that have
provided a rich environment to learn and grow. I would like to acknowledge my funding
from NIH diversity initiatives. I would like to thank my committee members for graciously
engaging in my dissertation research.

	
  

iii	
  

TABLE OF CONTENTS
Dedication .............................................................................................................. ii
Acknowledgments ................................................................................................. iii
List of Abbreviations ............................................................................................ viii
List of Tables ......................................................................................................... xi
List of Figures....................................................................................................... xii
Chapter 1 – Introduction..................................................................................... 1
1.1

Proteases in cancer ...................................................................... 1

1.2

Cathepsin B……………….……….…………….…………………… 9

1.3

Importance of cellular context: In vitro study of cancer in 3D .... 15

1.4

Acid-mediated invasion hypothesis ............................................ 17

Chapter 2 -- Materials and Methods ................................................................ 22

	
  

2.1

Materials ..................................................................................... 22

2.2

Tissue culture ............................................................................. 23

2.3

3D culturing................................................................................. 27

2.4

Live cell assays for proteolysis and active cysteine cathepsins . 27

2.5

MTT Assay .................................................................................. 32

2.6

Proliferation Assay ...................................................................... 35

2.7

Cell Viability Assay ..................................................................... 35

2.8

Fluorometric Activity Assay for Cathepsin B ............................... 36

2.9

Immunoprecipitation of ABP-bound cysteine cathepsins............ 37

2.10

Animals ....................................................................................... 38

2.11.

In vivo imaging of active cysteine cathepsins ............................. 38

iv	
  

2.12

Immnunohistochemistry of orthotopic tumors ............................. 39

2.13

RNA isolation for Microarray ....................................................... 40

2.14

Microarray pathway analysis using biocomputational software .. 41

2.15

Statistical analysis ...................................................................... 42

Chapter 3 – Contribution of Cysteine Cathepsins, Including Cathepsin B,
to Proteolysis ............................................................................... 43
3.1

Introduction ................................................................................. 43

3.2

Results ........................................................................................ 46
3.2.1

Live-cell imaging of 3D rBM overlay cultures confirms
presence of active proteases and proteolysis .................... 46

3.2.2

Acidic pHe enhances degradation of collagen IV ............... 47

3.2.3

Human carcinoma cells exhibit an acid-resistant
phenotype in 3D rBM overlay culture ................................. 50

3.2.4

Acidic pHe increases pro and active cathepsin B ............... 52

3.2.5

Inhibition of cathepsin B decreases degradation of
collagen-IV .......................................................................... 54

3.3

3.2.6

At Acidic pHe GB123 is increased pericellularly ................. 57

3.2.7

GB123 is detected in tumors in vivo ................................... 66
Discussion .................................................................................. 71

Chapter 4 -– Elevated STAT1 Signaling in DCIS Cell Lines Revealed by
Microarray Analysis .................................................................... 76

	
  

4.1

Introduction ................................................................................. 76

4.2

Results and Discussion .............................................................. 80

v	
  

4.2.1

Microarray data collection ................................................... 80

4.2.2

Parsing microarray data...................................................... 81

4.2.3

Commonly upregulated genes ............................................ 83

4.2.4

Unique rigorous examination using IPA pathway analysis . 89
4.2.4.1

SScore ..................................................................... 89

4.2.4.2

Genespring quality controls ..................................... 91

4.2.4.3

Commonalities among the three DCIS cell lines ... 101

4.2.4.4

IPA core analysis ................................................... 103

Summary and Future Directions ....................................................................... 112
References ........................................................................................................ 117
Abstract ............................................................................................................. 146
Autobiographical Statement .............................................................................. 148

	
  

vi	
  

LIST OF ABBREVIATIONS
2D

Two-dimensional

3D

Three-dimensional

ABP

Activity-based probe

ATCC

American Type Culture Collection

BL

Basal-like

CTSB

Cathepsin B

DCIS

Ductal carcinoma in situ

DMEM

Dulbecco's Modified Eagles Medium

DMEM/F12

Dulbecco's Modified Eagle's Medium/Nutrient F-12 Ham

DMSO

Dimethyl sulfoxide

DQ-collagen IV

Dye-quenched type IV collagen

EDU

5-ethynyl-2´-deoxyuridine

EGF

Epithelial Growth Factor

EHS

Engelbreth-Holm Swarm

ER

Estrogen receptor

EthD-1

Ethidium homodimer-1

FBS

Fetal bovine serum

Formazan

1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan

GO

Gene Ontology

HEPES

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HER-2

Human epidermal growth factor receptor 2

Hyal-2

Hyaluronase-2

	
  

vii	
  

IM

Immunomodulatory

IPA

Ingenuity pathway analysis

LAR

Luminal androgen receptor

Luc

Luciferase

M

Mesenchymal

M171

Mammary Epithelial Media 171

MEGS

Mammary Epidermal Growth Factor Supplement

MeHS

Medical Subject Headings

MMP

Matrix metalloproteinase

MPR

Mannose-6-phosphate

MSL

Mesenchymal stem-like

MT-MMPs

Membrane type-MMPs

MTT

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

PBS

Phosphate buffered saline

pHe

Extracellular pH

PIPES

Piperazine-N,N_-bis(2-ethanesulfonic acid

PR

Progesterone receptor

rBM

Reconstituted basement membrane

RFP

Red fluorescent protein

Sscore

Significance score

TNBC

Triple negative breast cancer

TTSPs

Transmembrane serine proteases

uPA

Urokinase

	
  

viii	
  

uPAR

Urokinase plasminogen receptor

uPARAP

Urokinase plasminogen activator receptor associated protein

	
  

ix	
  

LIST OF TABLES
Table 4.1

Selected genes increased in expression at pHe 6.8 in at
least 4 out of 6 cell lines ........................................................ 82

Table 4.2

Top Gene Ontology biological processes, as determined by
Genomatix, for the commonly elevated genes among the
three DCIS cell lines at pHe 6.8 ............................................ 84

Table 4.3

Top Gene Ontology molecular functions, as determined by
Genomatix, for the commonly elevated genes among the
three DCIS cell lines at pHe 6.8 ............................................ 85

Table 4.4

Significant diseases, as determined by Genomatix, for the
commonly elevated genes among the three DCIS cell lines
at pHe 6.8 .............................................................................. 86

Table 4.5

Probes and corresponding genes changed at pHe 6.8 in
each of six cell lines .............................................................. 90

Table 4.6

Seven upregulated downstream target genes of STAT1driven interferon signaling ................................................... 107

	
  

	
  

x	
  

LIST OF FIGURES
Figure 1.1

Caveolae (A) and invadopodia (B) cluster proteases in
networks at the cell surface ..................................................... 6

Figure 1.2

Cathepsin B is a dual function protease ................................ 11

Figure 1.3

An acidic microenvironment is generated by tumors and
enhances invasion and degradation of the extracellular
matrix ..................................................................................... 14

Figure 1.4

Selection barriers impede the progression of cancer and give
rise to the hallmarks of cancer .............................................. 18

Figure 2.1

MCF10 progression series and other cellular models used .. 25

Figure 2.2

Live cell imaging of proteolytic activity .................................. 29

Figure 2.3

Active cysteine cathepsins and degradation fragments of
DQ-collagen IV could be detected in breast carcinoma cells
grown in 3D rBM overlay cultures ......................................... 31

Figure 2.4

Absorbance spectrum of commercially purified formazan,
the MTT reaction product, dissolved in DMSO...................... 33

Figure 2.5

Absorbance spectrum for formazan is the same for cells
cultured at pHe 7.4 and 6.8 ................................................... 34

Figure 3.1

Degradation of DQ-collagen IV was greater at an
acidic pHe.............................................................................. 48

Figure 3.2

Quantification of DQ-collagen IV degradation products on a
per cell basis for MDA-MB-231, Hs578T, and HCT116 3D
rBM overlay cultures.............................................................. 49

Figure 3.3

In the absence of cells, degradation products (green
fluorescence) could not be observed at either pHe 7.4
or 6.8 ..................................................................................... 50

Figure 3.4

MDA-MB-231 cells in 3D rBM overlay cultures exhibited
similar proliferation and viability at pHe 7.4 (white bar) and
6.8 (gray bar), indicating an acid-resistant phenotype .......... 51

Figure 3.5

Cathepsin B activity was increased at acidic pHe ................. 53

	
  

xi	
  

Figure 3.6

Degradation of DQ-collagen IV was reduced by inhibition of
cathepsin B............................................................................ 55

Figure 3.7

Incubation with 20 µM CA074 (B) did not increase cell death
as compared to that observed with DMSO (vehicle control,
A) in 3D rBM overlay cultures of MDA-MB-231-RFP cells
(red) ...................................................................................... 56

Figure 3.8

Total and pericellular active cysteine cathepsins in 3D rBM
overlay cultures of MDA-MB-231 breast carcinoma cells
were increased at pHe 6.8 .................................................... 58

Figure 3.9

Total and pericellular active cysteine cathepsins in 3D rBM
overlay cultures of Hs578T breast carcinoma cells were
increased at pHe 6.8 ............................................................. 59

Figure 3.10

Total and pericellular active cysteine cathepsins in 3D rBM
overlay cultures of HCT116 colon carcinoma cells were
increased at pHe 6.8 ............................................................. 60

Figure 3.11

Pericellular bound GB123 was reduced by E64, a broadspectrum inhibitor of cysteine proteases ............................... 62

Figure 3.12

Active cysteine cathepsins in MDA-MB-231 cells were
profiled by in-gel fluorescence with the ABP GB123.
Signals for GB123-bound cathepsin B and L were
identified by immunoprecipitation .......................................... 63

Figure 3.13

Active cysteine cathepsins B and L in MDA-MB-231 cells
were identified by sequential immunoprecipitation with
antibodies to cathepsins L, B and S ...................................... 64

Figure 3.14

Absence of GB123-bound cathepsin S in MDA-MB-231
cells was confirmed by sequential Immunoprecipitation with
antibodies to cathepsins S, B and L ...................................... 65

Figures 3.15

GB123 localizes to orthotopic MDA-MB-231 tumors in vivo,
indicating that active cysteine cathepsins are present in
these tumors.......................................................................... 67

Figure 3.16

In vivo buffering of tumor pHe reduced tumor binding of
GB123 ................................................................................... 68

Figure 3.17

Segmentation of viable tissue ............................................... 70

	
  

xii	
  

Figure 4.1

GeneSpring quality control for intensity of fluorescent
Signals................................................................................... 92

Figure 4.2

Profile plots for intensity of fluorescent signals indicative of
changes in transcripts ........................................................... 95

Figure 4.3

Quality control histograms illustrating the number (1-6) of
significantly changed probes at pH 6.8 to a single RefSeq
gene ID .................................................................................. 98

Figure 4.4.

Genes significantly changed at pHe 6.8 in three human
DCIS cell lines ..................................................................... 102

Figure 4.5

Top canonical pathways, as determined by IPA core
analysis, using the 102 genes identified in Figure 4.4......... 105

Figure 4.6.

Interferon signaling pathway illustrating that in response to
an acidic microenvironment STAT1 drives the
transcriptional regulation of downstream target genes........ 106

Figure 4.7

Interferon signaling pathway illustrating that in
non-transformed cells STAT1 does not drive the
transcriptional regulation of downstream target genes in
response to an acidic microenvironment ............................. 108

	
  

xiii	
  

	
  

1	
  

CHAPTER 1
INTRODUCTION
1.1

Proteases in canceri
For years proteases have been implicated as causal in invasive processes

in cancer (local and during metastatic spread). The complete repertoire of
proteases known to be associated with cancer, i.e., the cancer degradome,
includes proteases of five catalytic types: aspartic, cysteine, metallo, serine and
threonine (Edwards et al., 2008). Examples of proteases that represent the five
catalytic types are: cathepsin D (aspartic), caspases and cathepsin B (cysteine),
MMP-9 and ADAM10 (metallo), plasmin and cathepsin G (serine), and the
proteasome (threonine) (Rawlings et al., 2010).

Proteases are commonly

thought to be required only for degradation of extracellular matrices in order for
the cancer cell to move from its original site. However, the roles of proteases in
cancer are much broader, including roles in premalignant lesions, growth, and
angiogenesis.

Furthermore, the proteases themselves derive not only from

tumor cells, but also from the multiple cell types present in the tumor stroma,
e.g., fibroblasts, macrophages, mast cells, leukocytes, and endothelial cells.
Indeed, there is an extensive body of literature on “proteases in cancer” with over
7000 reviews found on pubmed. Despite all that has been found, there is still
much to unravel.
An impediment to determining how proteases function in tumors is that a
purified protease capable of cleaving a potential extracellular matrix substrate in
vitro may not be the protease or the single protease responsible for degradation
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of that substrate in vivo. Furthermore, any one protease may be targeted to
different substrates during the early and late stages of tumor progression (for
recent comprehensive reviews on proteases in cancer, see (Edwards et al.,
2008)). The in vivo functions of proteases are being studied through the use of
transgenic mice deficient in specific proteases.

Such studies have been

informative for pulling out specific functions of a single protease in vivo as
opposed to inhibitors that may affect other family members. There are several
reasons that suggest that this approach is not feasible for all proteases including:
1) the large number of proteases, 2) the interplay between proteases and their
endogenous inhibitors and activators, and 3) the redundancy among proteases
and the observations of compensatory changes in other proteases. The daunting
number, ~560, of proteases in the human genome limits studies in both cost and
time to explore each individually (Cal et al., 2007; Puente et al., 2003; Rawlings
et al., 2010). Cathepsin B is an example of a protease that needs to have a
strong consideration of the interplay with inhibitors/activators as a mechanism of
its regulation. Cathepsin B can self activate by cleavage of the pro-peptide or it
can be cleaved by another protease (e.g., Cathepsin D). Additionally, outside of
the lysosome the active enzyme is quickly inhibited by endogenous inhibitors
either stefins and cystatins depending on the localization intra or extracellularly,
respectively (Sloane et al., 1990). An example of the redundancy occurs for
lysosomal cysteine cathepsins in a transgenic murine model for the development
of mammary cancer that has established presence of cathepsin B at the surface -- in mice deficient in cathepsin B there is altered cell surface expression of
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cathepsin X (Vasiljeva et al., 2006). However, in addition to compensational
roles among proteases within the same catalytic-type family members, there are
additional challenges when considering all the different catalytic-types.

For

example the deficiency of a serine protease might result in alterations in a matrix
metalloproteinase (MMP), and these types of changes are harder to predict or
detect. Although the complexity of the biological roles of proteases might be
analyzed more successfully in genetically engineered murine cancer models in
which the protease gene alleles are latent, conditional or inducible (for review,
see (Tuveson and Jacks, 2002; Van Dyke and Jacks, 2002)), the use of such
models will likely be restricted to only a few proteases for the above reasons.
Tumor invasion and metastasis are often assumed to be processes that
involve only extracellular proteases and membrane proteases, e.g., MMPs,
membrane type-MMPs (MT-MMPs) such as MT1-MMP or MMP-14 and type II
transmembrane serine proteases (TTSPs) such as matriptase (for reviews (List,
2009; List et al., 2006; Strongin, 2010)). In addition to extracellular proteases
intracellular proteases are also, although less commonly, implicated in tumor
invasion and metastasis. Intracellular proteases frequently mediate invasion in
lower organisms such as parasites. Invasion of plasmodium and toxoplasma, the
parasites responsible for malaria and toxoplasmosis, respectively, occurs as a
result of the secretion of vacuolar cysteine proteases and can be abolished with
cysteine protease inhibitors (for reviews, see (Binder and Kim, 2004; McKerrow
et al., 2006; Rosenthal, 2004)). The working hypothesis in our laboratory has
been that the mammalian counterparts of these enzymes, i.e., the lysosomal
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cysteine cathepsins, play comparable roles in the invasive processes associated
with human cancers (for review, see (Mohamed and Sloane, 2006)).

As

discussed below, these proteases are secreted from tumor cells and some bind
to the cell surface. Whether the primary role of cysteine cathepsins in cancer is
pericellular, intracellular or both is not yet clear. We have shown that cysteine
cathepsins degrade extracellular matrix proteins intracellularly in highly invasive
BT59 breast carcinoma cells, yet pericellularly in less invasive BT20 breast
carcinoma cells (Sameni et al., 2000). Others have confirmed an intracellular
role of cysteine cathepsins in degradation of collagens, degradation that is
causally linked to invasive growth of mammary tumors (Curino et al., 2005),
progression of prostate cancers (Kogianni et al., 2009) and migration and
invasion of glioma cell lines (Takahashi et al., 2011). The collagens are taken up
into the lysosomes via the endocytic collagen receptor uPARAP (urokinase
plasminogen activator receptor associated protein)/Endo180. Activity of MT1MMP, activation of MMP-2 by MT1-MMP and activity of urokinase (uPA) all have
been shown to be regulated by uPARAP (Messaritou et al., 2009), indicative of
functional interactions among pericellular and intracellular proteases that
contribute to collagen degradation.
Sylven and colleagues reported an association of lysosomal proteases
with cancer in 1957 (Sylven and Malmgren, 1957) and later specifically an
association of cathepsin B with tumor cell surfaces (Sylven et al., 1974).
Subsequent studies reported secretion of lysosomal proteases: cathepsin B from
human breast carcinoma explants (Poole et al., 1978; Recklies et al., 1980);
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cathepsin L, another cysteine protease, from transformed murine fibroblasts (Gal
and Gottesman, 1986); and cathepsin D, an aspartic protease, from the human
MCF7 breast carcinoma cell line (Morisset et al., 1986).

Studies by our

laboratory established an association between expression of cathepsin B and
malignancy of murine melanomas (Sloane et al., 1981; Sloane et al., 1982). We
identified mechanisms that increase secretion of pro and mature forms of
cathepsin B and a binding partner that mediates association of pro-cathepsin B
with caveolar lipid rafts (Figure 1.1A) and invadopodia (Figure 1.1B) on the tumor
cell surface (for reviews, see (Cavallo-Medved et al., 2011; Mohamed and
Sloane, 2006; Rothberg et al., 2012; Victor and Sloane, 2007)).

	
  

	
  

Figure 1.1A.
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Figure 1.1B.
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Figure 1.1 Caveolae (A) and invadopodia (B) cluster proteases in networks
at the cell surface. There are structural similarities between caveolae and
invadopodia e.g. both require caveolin-1 and lipid rafts for formation. (A)
Caveolae are a subset of lipid rafts in the plasma membrane, which form flaskshaped invaginations as a result of the interactions of dimerized caveolin-1.
Many proteases associated with extracellular matrix degradation are localized to
caveolae, e.g., plasmin[ogen], MMP-2, -9 and 14 and cathepsin B (CTSB). For
some proteases this is the result of binding to receptors, e.g., uPA to uPAR and
plasmin[ogen] and CTSB to the annexin II heterotetramer. MMP-14 is a
transmembrane MMP, which is also known as MT1-MMP, whereas uPAR is
inserted into the membrane by a GPI anchor and is also part of a trimeric
complex with β1-integrin and uPARAP, an endocytic receptor associated with
collagen uptake. (B) Invadopodia are membrane protrusions associated with
filamentous actin and extracellular matrix degradation. MMP-14 and fibroblast
activation protein (FAP) or seprase accumulate in invadopodia membranes. In
the case of other proteases such as, MMP-2 and lysosomal cysteine cathepsins
(e.g., CTSK, CTSL, CTSX), there is increased secretion from invadopodia.
Depicted here is a lysosome releasing several cysteine cathepsins following
trafficking to the membrane on a microtubule (grey). The hexagon shapes
represent MMPs and pro-MMPs have an additional swoosh representing their
pro-peptide.
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Cathepsin B
Cathepsin B is a cysteine protease and a member of the Clan-C1-papain

family. The human gene for cathepsin B is located within on chromosome 8 p22
(Fong et al., 1992).

Cathepsin B is transcribed as a 339 amino acid pre-

proenzyme that cotranslationally loses the 17 amino acid pre-peptide as it enters
the rough endoplasmic reticulum (reviewed in (Moin et al., 1992; Mort and Buttle,
1997)). Pro-cathepsin B has a molecular weight of 43- to 46-kDa depending on
its glycosylation status. Normal trafficking of pro-cathepsin B to the lysosome
follows the classic lysosomal mannose-6-phosphate pathway (Tanaka et al.,
2000). In this pathway [reviewed in (Coutinho et al., 2012)], lysosomal proteins
containing the N-linked oligosaccharides tagged with the mannose-6 phosphate
are recognized and bound by mannose-6-phosphate receptors (MPR) in the
trans-Golgi. They remain associated as the budding vesicles are released and
sorted to deliver the lysosomal hydrolases (e.g., cathepsin B) to the endosomes
that will ultimately develop into mature lysosomes. Pro-cathepsin B disassociates
from MPRs in response to a drop in pH characteristic of the late endosomes at
~pH 6 and then the empty receptors are recycled back to Golgi.

In the

lysosomes cathepsin B undergoes maturation to its active form as either the 31kDa single or 25/26-kDa plus 5-kDa double chain form linked by a disulfide
bridge (Kawabata et al., 1993; Ritonja et al., 1985). In the lysosomes cathepsin
B has a broad substrate specificity to help in degradation and protein turnover
(Rawlings et al., 2010).
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Cathepsin B is a bi-lobal protein with the active site interface between two

globular domains. Uniquely among other C1-papain family members cathepsin B
is a dual functional protease because in addition to catalyzing peptide cleavages
as an endopeptidase it can also cleave substrates as an exopeptidase (peptidyldipeptidase) (Barrett and Kirschke, 1981) (Figure 1.2). The evolutionary origin of
cathepsin B suggests that it may have originated as endopeptidase similar to
other C1-papain family members, but the 21 amino acid insertional group termed
“occluding loop” gives cathepsin B an additional and presumably dominant
function as a carboxypeptidase.

Only three other family members have a

catalytic function other than endopeptidase activity: cathepsins H and X and
dipeptidyl-peptidase-1 are both exclusively exopeptidases (Rawlings et al.,
2010). Mouse models have supported that the dual activity of cathepsin B is
functional in vivo because cathepsin L (endopeptidase) and cathepsin X
(exopeptidase) have been shown in different experimental models to
compensate for the absence of cathepsin B (Sevenich et al., 2006; Sevenich et
al., 2010; Vasiljeva et al., 2006).
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Figure 1.2. Active cathepsin B is a protease with dual functions as a result of an
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Mature cathepsin B is active at both slightly acidic and neutral pH with the dual-

pH-optimum being regulated by an occluding loop (Illy et al., 1997; Nagler et al.,
1997).

This flexible occluding loop has pH-sensitive histidine residues (His110

and His111) that stabilize the occluding loop within the prime region of the activesite cleft (Musil et al., 1991; Nagler et al., 1997). In an acidic environment the
occluding loop partly blocks one side of the active site interface and provides an
anchor for C-terminal substrates allowing successful proteolytic cleavage of
dipeptides at the carboxy terminus of proteins (Figure 1.2).

In a neutral

environment the deprotonation of histidines provides more flexibility in the
occluding loop and further exposes the active site allowing substrates to more
readily displace the occluding loop, leading to cleavage of internal peptide bonds
within protein substrates (Khouri et al., 1991; Nagler et al., 1997). The
endopeptidase catalytic activity has a more neutral pH optima, around pH 7.4
(Khouri et al., 1991; Nagler et al., 1997); others have suggested that cathepsin B
has endopeptidase activity at low pH in studies using synthetic fluorescent
peptide substrates (Ruzza et al., 2006).
This dual function protease has been implicated for many years as a
mediator of invasion and metastasis and is of interest to this study because of its
ability to function within the pH range found in the interstitial fluids around human
breast tumors. In breast and other types of cancers cathepsin B has been shown
to have an altered intracellular trafficking pattern (Campo et al., 1994), an
association with the plasma membrane, and to be secreted in both active and
inactive forms (Poole et al., 1978; Rozhin et al., 1994). Aberrant cathepsin B
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activity and localization have been attributed in part to alterations in the
expression of cathepsin B as mediated by gene amplification, increased
transcription, increase in mRNA stability, use of alternative promoters, and
alternative splicing (Yan and Sloane, 2003). Other cells besides transformed
epithelial

cells

have

elevated

levels

of

cathepsin

B

in

the

tumor

microenvironment, such as cancer-associated macrophages (Campo et al.,
1994; McKerrow et al., 2000). The Sloane laboratory has found that growth of
human breast fibroblasts on collagen I alters cell morphology and results in
increased expression of cathepsin B and secretion of pro-cathepsin B (Koblinski
et al., 2002). Furthermore, an acidic extracellular pH (pHe) has been shown to
induce redistribution of cathepsin B from perinuclear lysosomes towards the cell
periphery and/or secretion in melanoma and breast cancer cells (Rozhin et al.,
1994); for review see (Rothberg et al., 2012) and Figure 1.3.
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Figure 1.3. An acidic microenvironment is generated by tumors and
enhances invasion and degradation of the extracellular matrix. The scissors
indicate cleavage of the basement membrane protein collagen IV. In response to
acidic pH pericellularly, vesicles redistribute to the cell periphery via a
microtubule-dependent process, possibly leading to the observed secretion of
active CTSB from lysosomes and proCTSB from secretory vesicles from breast
cancer cells. This also includes secretion of lysosomal glycosidases such as
hyaluronase-2 (Hyal-2), which cleaves hyaluronan and releases bioactive
molecules that had bound to this matrix component (stars).
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Importance of cellular context: In vitro study of cancer in 3D
Historically, in vitro tissue culture conditions have not taken into account

the non-cellular tumor microenvironment (Maltman and Przyborski, 2010). One
of the key components of a cell’s environment is the matrix that surrounds it (Lu
et al., 2012). There are many changes that occur in cells that are cultured with or
without extracellular matrix (Howlett and Bissell, 1993). Limitations of traditional
tissue culture methods include, but are not limited to: loss of tissue-specific
architecture, mechanical and biochemical signaling, and types of cell-cell
communication. These changes lead to altered downstream gene expression
and changes in metabolism. The lost signaling and attachment cues can be
restored along with proper polarization in 3D culture systems (Petersen et al.,
1992); further reviewed in (Bissell and Radisky, 2001).
There are many matrices to choose from for a 3D scaffold for solid tumor
growth. What makes a good matrix for 3D growth and study of proteases (with a
focus on imaging)? It should have biological context with components of the
natural environment, e.g., recognizable matrix for proper integrin signaling for
proper polarization. One should be able to easily separate the matrix from the
cells to assess changes in select proteins, DNA and RNA. To observe proteolytic
activity the matrices should be degradable.

However, others contend that

matrices don't need to be degraded to allow movement of tumor cells through
stromal tissues (Friedl and Wolf, 2003; Wolf et al., 2003a; Wolf et al., 2003b;
Wyckoff et al., 2006). The matrix should be translucent for imaging by confocal
microscopy and detection of fluorescent markers in real-time (Smith et al., 2010).
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Matrix degradation should be quantifiable after protease cleavage such as
through use of fluorescence, biotin, and/or antibodies (Jedeszko et al., 2008;
Moin et al., 2012). Several matrices can meet these requirements such as those
derived

by

electrospinning

membranes (rBM).

or

hydrogels,

e.g.,

reconstituted

basement

Additionally there are many other matrix systems that

support 3D tissue growth albeit in non-degradable matrices (i.e, electrospun
synthetic fibers). There are benefits and caveats to each, but all try to address
the limitations associated with 2D cultures.
Our laboratory conducts studies in 3D using a rBM overlay model
optimized by Brugge and colleagues (Debnath et al., 2002; Debnath et al., 2003).
Natural components of basement membranes are isolated and purified from
Engelbreth-Holm-Swarm (EHS) sarcoma tumor extracts grown in vivo, marketed
as MatrigelTM or CultrexTM. The history and uses of the rBM are reviewed in
Kleinman and Martin (Kleinman and Martin, 2005). This commercially available,
easy to store and manipulate basement membrane extract provides physiological
context. Indeed, elegant studies by Bissell and colleagues using rBM and diploid
breast cells established integrin dependent polarity and functional morphology
characteristic of the site of origin, i.e., breast acinar ductal cells differentiating into
milk- or casein-producing epithelium (Bissell et al., 2002; Petersen et al., 1992).
The main caveat of the rBM 3D models is the unpredictability of these naturally
derived extracellular matrixes which are undefined and could lead to altered
behaviors or signaling mechanisms due to batch-to-batch variability. To over
come this limitation our laboratory and others, are using the same lot as much as
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possible throughout a study to reduce the variability. In addition to considering
an appropriate matrix for the studies, other non-cellular microenvironmental
aspects should be considered, such as the pH.
1.4 Acid-Mediated Invasion Hypothesis
A majority of solid tumors have an acidic microenvironment (Wike-Hooley
et al., 1984) with the extracellular pH (pHe) in tumors ranging from 5.3-7.2
(Gillies et al., 2002; van Sluis et al., 1999). Acidification has been attributed to a
combination of factors including chaotic tumor vasculature, increased glycolysis
and diminished buffering capacity of tumor interstitial fluids (Stubbs et al., 1994).
These factors lead to high concentrations of extracellular lactic acid surrounding
the tumors. The key mediator --- increased glycolysis --- is a component of
reprogramming of energy metabolism, one of the emerging hallmarks of cancer
(Hanahan and Weinberg, 2011); also see (Figure 1.4).

The concept that

metabolism is altered in cancer dates back to the observation made by Otto
Warburg that tumor cells exhibit increased glucose breakdown via glycolysis
despite the presence of oxygen (Warburg et al., 1927). Byproducts of elevated
glycolytic activity result in an acidic pHe that varies among different types of solid
tumors and is heterogeneous within a single tumor (Gillies et al., 2002; van Sluis
et al., 1999; Wike-Hooley et al., 1984).
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Figure 1.4. Selection barriers impede the progression of cancer and give
rise to the hallmarks of cancer. The fundamental idea driving our study is that
adaptation of cancer cells overcomes selection barriers and result in the
hallmarks of cancer. Cancers must overcome all of the barriers, but this can be
accomplished in various ways.
For example, alterations in a single
multifunctional protein such as Ras or hypoxia-inducible factor 1α may initially
serve to overcome one barrier, but then accelerate the subsequent pace of
somatic evolution by lowering other barriers. The barriers are used as “crucial
mathematical parameters” to model of the acid-mediated invasion hypothesis
(Gatenby and Gillies, 2008). Our study looks at the pre-malignant to invasive
stages of breast cancer where intermittent hypoxia selects for cancer cells that
have an altered metabolic phenotype of anaerobic glycolysis and that consume
large amounts of glucose. This metabolic shift can remain even in the presence
of adequate vasculature and oxidation. Glycolysis produces large quantities of
lactic acid, which is secreted and, when coupled with other factors, results in an
acidic tumor microenvironment. This acidosis creates a supportive environment
for basement membrane degradation and invasion through increased activity of
proteases.
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Acidification of the tumor microenvironment has been shown to cause acid-

mediated toxicity in the surrounding normal cells and providing empty space for
tumor cell proliferation and invasion through proteolytic remodeling of
extracellular matrix (Figure 1.4). The cancer hallmark of resistance to apoptosis
can be subcategorized to resistance to apoptosis mediated by acid-mediated
toxicities (Gatenby and Gillies, 2008). Normal cells begin undergoing cell death
at pH < 7.3 with an apoptotic threshold at pH 7.1 (Casciari et al., 1992).
Acidifying the microenvironment adversely affects surrounding normal cells
pushing them towards death either by necrosis, apoptosis, or other means,
whereas the cancer cells largely resist acid-mediated death (Martin et al., 2010).
During the premalignant stages of tumorigenesis, cancer cells develop a
resistance to the toxicity of an acidic microenvironment (Gatenby et al., 2007).
Acid-resistant cells survive and proliferate in low pH environments. One recently
suggested mechanism by which cancer cells adapt and survive in an acidic
microenvironment is the up-regulation of chronic macroautophagy (Wojtkowiak et
al., 2012).

Autophagy as a survival mechanism in cancer is controversial.

Mashima et al. (2009) alternatively offered acytl-CoA synthetase 5 activities as a
probable mediator for the acidosis survival mechanism in glioma cells.

The

acidic tumor microenvironment effectively eliminates normal cells that compete
for the same nutrients and space as the cancer cells, giving the cancer a survival
advantage over the normal cells.
Acidosis assessed via elevated glycolysis has been shown to persist in
areas of adequate oxygen (Cherk et al., 2006; Fukumura et al., 2001; Hjelmeland
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et al., 2011). The acid-mediated invasion hypothesis is supported by a large
quantity of correlative data, including: 1) reaction diffusion modeling (Gatenby
and Gawlinski, 1996); 2) increased metastasis formation following acid-pretreatment (Moellering et al., 2008; Rofstad et al., 2006; Schlappack et al., 1991);
3) peritumoral acidosis measured by intravital microscopy (Gatenby et al., 2006)
and 4) inhibition of spontaneous and experimental metastasis following acidneutralization with buffers (Ibrahim-Hashim et al., 2012; Ibrahim-Hashim et al.,
2011a; Ibrahim-Hashim et al., 2011b; Robey et al., 2009).
Prior experiments have shown that low pH is associated with increased
protease activity (Martinez-Zaguilan et al., 1996) and increased release of active
cysteine cathepsins in 2D culture models (Robey et al., 2009; Rozhin et al.,
1994). This increase in active proteases may enhance invasion since in tumor
xenografts invasion has been shown to occur more often in regions where the
pHe is acidic (Estrella et al., 2013). Previous studies from our laboratory and
others suggest that an acidic peritumoral microenvironment provides a
supportive environment for proteases that have an acidic pH optimum, such as
cathepsin B or other lysosomal proteases.

Indeed, of the 11 cysteine

cathepsins, more than half have been linked to breast cancer progression:
cathepsins B, L, H, K, S, V and X (Watson and Kreuzaler, 2009). An acidic pHe
induces redistribution of endosomes and lysosomes to the cell surface and
increases release of cysteine cathepsins (Glunde et al., 2003; Rozhin et al.,
1994; Steffan et al., 2009). My study builds off these prior studies as I examine
the effects of an acidic pHe in the breast tumor microenvironment.
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CHAPTER 2
MATERIALS AND METHODS
2.1

Materials
Dimethyl sulfoxide (DMSO), Dulbecco’s Modified Eagles Medium

(DMEM), Dulbecco's Modified Eagle's Medium/Nutrient F-12 Ham (DMEM/F12),
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), hydrocortisone,
insulin from bovine pancreas, NaHCO3, piperazine-N,N′-bis(2-ethanesulfonic
acid)

(PIPES),

thiazolyl

blue

formazan

(1-(4,5-dimethylthiazol-2-yl)-3,5-

diphenylformazan, and all other chemicals not otherwise noted were obtained
from Sigma (St. Louis, MO). Fetal bovine serum (FBS) was purchased from
Hyclone (Logan, Utah); Epithelial Growth Factor (EGF) from R&D Systems
(Minneapolis, MN); Mammary Epithelial Media 171 (M171) and Mammary
Epidermal Growth Factor Supplement (MEGS) from Cascade Biologics
(Portland, OR); Z-Arg-Arg-NHMec (Bachem, Torrence, CA); CA074, E64, from
Peptides International (Louisville, KY); pimonidazole HCl from Hypoxyprobe,
(Burlington, MA); and Ventana OmniMap anti-Rabbit HRP from Roche
(Indianapolis, IN). Reconstituted basement membrane (rBM): in vitro studies
used reduced growth factor CultrexTM from Trevigen (Gaithersburg, MD); in vivo
studies used MatrigelTM (BD Biosciences, San Jose, CA). CellTrackerTM orange,
Click-IT EDU (5-‐ethynyl-‐2´-‐deoxyuridine) microplate assays, DQ-collagen IV,
Hoechst 33342, horse and goat serum, live/dead kit, 3-(4,5-Dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) and trypsin-EDTA were purchased from
Life Technologies (Grand Island, NY). Pierce Protein A/G Plus Agarose beads
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(Thermo Scientific, Rockford, IL) and anti-rabbit cathepsin B, anti-rabbit preimmune IgG (Moin et al., 1992), anti-rabbit cathepsin S (a kind gift of Dr. Boris
Turk, Jozef Stefan Institute, Ljubljana, Slovenia), anti-goat cathepsin S (R&D
Systems) and anti-rabbit cathepsin L (Dr. Ekkehard Weber, Martin Luther
University, Halle, Germany) antibodies were used for immunoprecipitations.
GB123, an activity based probe (ABP) for cysteine cathepsins (Blum et al.,
2005), was provided by Dr. Matthew S. Boygo (Stanford University, Palo Alto,
CA).
2.2

Tissue Culture
We utilize the MCF10A progression series to model breast cancer

progression the as well as other human derived cell lines to complement this
system. Figure 2.1 demonstrates the MCF10A progression series related to the
progression of ductal breast carcinoma as well as indicating the other cell lines
used in this study. In addition to the MCF-10A breast cancer progression series
(MCF10A, MCF10-AT1, MCF10-AT3B, MCF10.DCIS, and MCF10-CA1D)
obtained from the Cell Lines Resource (Karmanos Cancer Institute, Detroit, MI)
other human cell lines used and where they are from include: normal mammary
myoepithelial cells (N1ME) were a kind gift from Dr. Kornelia Polyak (DanaFarber Cancer Institute, Boston, MA); tumor-associated human mammary
fibroblasts (WS-12Ti) were a kind gift from Steve Santner (KCI, Detroit, MI).
Invasive triple negative breast cancer (TNBC) MDA-MB-231 [American Type
Culture Collection (ATCC)] and MDA-MB-231 stably transfected with red
fluorescent protein (RFP) and luciferase (Luc) (Robey et al., 2009), and Hs578T
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from Dr. Raymond Mattingly were used along with colon carcinoma HCT116 from
ATCC, and patient-derived DCIS breast cells SUM 102 and SUM 225 as a kind
gift from Dr. Stephen P. Ethier (KCI / MUSC). Low passages of all cells were
maintained at pH 7.4 with antibiotics (penicillin/streptomycin) in the absence of
phenol red due to its estrogenic properties under humidified conditions under
atmospheric oxygen levels and 5% CO2. Cells were monitored by microscopy to
confirm that they maintained their original morphology and were regularly
screened for mycoplasma by microscopy (MycoFluor, Invitrogen) and RT-PCR
(LookOut, Sigma).

For subculturing, cells were detached from tissue culture

treated flasks with 0.05% trypsin-EDTA (except MCF10.DCIS cells which were
detached using 0.25% Trypsin-EDTA).

MCF10-A, -AT1, and -AT3B were

maintained in DMEM/F12 supplemented with 5% horse serum, 5 ng/ml EGF, 100
µg/ml insulin, and 1 µg/ml hydrocortisone.

MCF10-DCIS and –Ca1D were

maintained in DMEM/F12 supplemented with 5% horse serum. WS-12Ti were
maintained in DMEM/F12 medium supplemented with 10% FBS. The MDA-MB231-RFP/LUC, Hs578T, and HCT116 cells were maintained in DMEM
supplemented with 10% FBS. SUM102 and SUM225 were maintained in Ham's
F-12 medium supplemented with 10% fetal bovine serum and N1ME cells were
maintained in M171 media supplemented with MEGS.
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Figure 2.1. MCF10 progression series and other cellular models used. The
MCF10 progression series consists of several isogenic cell lines that model
breast cancer progression from a non-transformed, spontaneously immortalized
diploid cell line to invasive ductal carcinoma of the triple negative breast cancer
(TNBC) subtype. Shown in this image from the breastcancer.com website is a
cartoon of the stages of breast cancer progression as visualized through a cross
section of a duct. In the normal duct, there is a single layer of ductal epithelial
cells, a phenotype corresponding to structures formed in vitro in 3D cultures by
MCF-10A cells. The subsequent derivatives of the 10A cell line are shown in
pink boxes alongside corresponding to stages of malignant progression. In
addition to the MCF10.DCIS and CA1D cells, we analyzed patient-derived cell
lines that represent DCIS (SUM 102 and SUM 225) and highly malignant
carcinomas (MDA-MB-231 and Hs578T), depicted here in blue boxes. We also
used human breast tumor-associated fibroblasts (WS-12Ti) and human normal
breast myoepithelial cells (N1ME) and one non-breast cancer cell line, i.e.,
HCT116 colon carcinoma cells, as depicted in the white boxes.
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3D culturing
We use an overlay method for growing 3D structures of cells designed by

Bissell and colleagues (Bissell et al., 1999; Howlett and Bissell, 1993; Weaver
and Bissell, 1999) and further optimized by Joan Brugge and colleagues
(Debnath and Brugge, 2005; Debnath et al., 2002). Single cell suspensions of an
appropriate number of cells per desired volume are placed on solidified reduced
growth factor Cultrex. When the cells are adherent the medium containing 2%
reduced growth factor Cultrex is placed over the cells. For detailed methods see
(Sameni et al., 2012). For experiments testing the effects of pH, the medium
were additionally buffered to maintain pH 7.4 or 6.8 with 2 g/L sodium
bicarbonate, 25 mM of PIPES, and HEPES and then incubated overnight at 37
°C in 5% CO2 (Robey et al., 2009).
2.4

Live Cell Assays for Proteolysis and Active Cysteine Cathepsins
A detailed protocol for the live cell proteolysis assay has been published

(Jedeszko et al., 2008). Briefly, glass coverslips in 35-mm dishes were coated
with 45 µl of Cultrex rBM containing 25 mg/ml of DQ-collagen IV (Figure 2.2) and
placed in a 37 °C incubator for 10 min to allow solidification. Approximately
50,000 cells were seeded on top of the Cultrex and incubated at 37 °C for 30-60
min until adherent, at which point either pH 7.4 or 6.8 culture media containing
2% rBM were applied (Figure 2.2). Media were changed the following day. For
inhibitor studies, 20 µM CA074/E64 or an equal volume of DMSO was added to
the Cultrex before solidification as well as to the media overlay. To visualize
active cysteine cathepsins the same setup applies with the addition of 1 mM of
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GB123, an ABP (Blum et al., 2005; Blum et al., 2007), to media for 16-18 hours
prior to imaging (Figure 2.2).

Cells were washed thoroughly in phosphate

buffered saline (PBS) to remove any unbound probe and returned to probe-free
complete growth medium at either pH 7.4 or 6.8 for at least one hour prior to
imaging. The nuclei were labeled with Hoechst 33342 just before imaging. All
experiments were imaged with a Zeiss LSM 510 META NLO confocal
microscope using a 40X water-dipping objective to capture the 3D structures
(Figure 2.3A).

Cell number was determined with Volocity™ software (Figure

2.3B). The intensity of the fluorescent signal per cell was measured using
MetaMorph™ and Volocity™ software. Localization of active cysteine cathepsins
was determined using MetaMorph™ software. RFP expression or CellTrackerTM
orange staining were utilized to determine cell boundaries, as described
previously (Jedeszko et al., 2008) (Figure 2.3).
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Figure 2.2. Live cell imaging of proteolytic activity. A) Cartoon of the
confocal imaging setup, showing the dipping lens submerged in buffered culture
medium (DMEM) maintained at either neutral (7.4) or slightly acidic (6.8) pH and
containing 2% rBM. Fluorescent cells either expressing RFP or pre-labeled with
CellTracker Orange are grown in 3D rBM overlay cultures. B) DQ-collagen IV is
mixed with Cultrex prior to solidification and upon proteolytic cleavage emits
green fluorescence. C) Chemical structure of GB123, an activity-based probe
(ABP) for cysteine cathepsins, is shown. The ABP is added to the media the day
before imaging and washed to remove unbound probe prior to imaging. GB123
covalently binds to its target proteases, e.g., cathepsin B, allowing for Cy5
detection of the protease.
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A

B

C

D

Figure 2.3. Active cysteine cathepsins and degradation fragments of DQcollagen IV could be detected in breast carcinoma cells grown in 3D rBM
overlay cultures. A) 3D reconstruction of optical sections taken through the
entire volume of an MDA-MB-231 3D culture: with red representing RFP in the
cytoplasm; blue representing Hoechst 33342 stained nuclei; green representing
degradation products of DQ-collagen-IV; and cyan representing GB123 bound to
active cysteine cathepsins. B) Illustration of spatial separation in 3D of nuclei for
Figure
2.3
enumeration.
C and D) Single optical sections through the equatorial plane,
fluorescence was evenly increased to visually differentiate with mask (white)
illustrating measured DQ-collagen IV degradation fragments and ABPs bound to
cysteine cathepsins, respectively. Bar, 22.6 µm.
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MTT Assay
Literature searches suggested disagreement as to the best wavelength to

measure the formazan absorbance peaks. To determine optimal wavelengths for
our assay, an absorbance profile from 200-700 nm was recorded for purified
thiazolyl blue formazan at a 1:5 dilution of 1 mg/ml in DMSO using a BioSpec1601, Shimadzu Corporation (Kyoto, Japan) (Figure 2.4).

The multiple

wavelengths published might suggest lack of available filters in the plate readers
used. Plumb et al. (1989) demonstrated that pH of the dilutants can causes
shifts in the absorbance spectrums. Here only DMSO was used to lyse cells and
dissolve the formazan precipitates; nonetheless, absorbance profiles were
recorded for pooled formazan products from live cells after 3 days of growth in
3D rBM overlay cultures at either 7.4 or 6.8 to eliminate the possibility of
absorbance profile shifts under the conditions used for our studies (Figure 2.5).
A large volume of product solution was required to obtain an absorbance
spectrum. Therefore, cellular metabolized MTT-products (i.e., formazan) were
pooled from multiple cell lines, including ones that were not acid-resistant. This
attributed to the lower absorbance readings at pHe 6.8.
For this assay, each well of a 96-well plate was coated with 15 µl Cultrex
before adding ~1500 cells/well, followed by 200 µl of either pH 7.4 or 6.8 DMEM
media containing 2% Cultrex. On the day of the assay 50 µl of MTT (5 mg/ml)
stock solution was added to each well to a final concentration of 1 mg/ml MTT.
The plate was incubated at 37 ˚C for 3 hours to allow formation of the formazan
crystal product. Media were removed and replaced with 150 µl DMSO while
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shaking at room temperature. Absorbance values were read at 485 nm on a

Absorbance'

Tecan Spectrafluor Plus (Salzburg, Austria).

Figure 2.4. Absorbance spectrum of commercially purified formazan, the
MTT reaction product, dissolved in DMSO. Lines at 488 and 590 indicate
available filter settings for the 96-well Tecan Spectrafluor Plus plate reader.

Figure'2.4'
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Absorbance'

A

Absorbance'

B

Figure 2.5. Absorbance spectrum for formazan is the same for cells
cultured at pHe 7.4 and 6.8. Absorbance spectra of dissolved formazan
products from cells cultured at either pH 7.4 (A) or pH 6.8 (B) are shown. Lines
at 488 and 590 indicate available filter settings for the 96-well Tecan Spectrafluor
Figure'2.5'
Plus plate reader.
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Proliferation Assay
Cell proliferation was measured via a Click-iT EdU (5-ethynyl-2’-

deoxyuridine) microplate assay in which incorporation of the nucleoside analog,
EdU, into DNA during active DNA synthesis is assessed. For this assay, each
well of a 96-well plate was coated with 15 µl Cultrex before adding ~1500
cells/well. To each well, 200 µl of either pH 7.4 or 6.8 DMEM media containing
2% Cultrex was added. On day two, EdU was added and the next day the assay
was performed according to the manufacturer’s protocols. Fluorescence values
were read at 568/585 nm on a Gemini SpectraMax (Molecular Devices,
Sunnyvale, CA).
2.7

Cell Viability Assay
To distinguish living from dead or dying cells under our assay conditions, a

Live/Dead kit was used. This assay utilizes differential properties of live and
dead cells to fluorescently distinguish them.

Live cells have ubiquitous

intracellular esterase activity, which converts a nonfluorescent cell-permeable
calcein AM to fluorescent calcein (ex/em ~494 / ~517 nm). Dead cells, with
damaged membranes, allow ethidium homodimer-1 (EthD-1) to enter and bind
nucleic acids thus emitting fluorescence (ex/em ~528/~617 nm). For this assay
glass coverslips were coated with 45 µl of Cultrex and placed in a 35-mm dish.
Cells (~5,000) were seeded on the Cultrex until adherent then covered with either
pH 7.4 or 6.8 media containing 2% rBM. Media were changed every three days.
At the selected endpoints cultures were incubated with assay reagents (PBS
containing both four µM EthD-1 and two µM calcein AM) for 30 minutes before
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imaging six to eight fields of view per coverslip at both 485 and 530 nm. For this
assay calcein positive cells (green) were considered alive, while EthD-1 positive
cells (red) were considered dead. However, for cells expressing RFP (MDA-MB231-RFP/Luc cells) the RFP and EthD-1 signal overlap making all the cells “red”,
so calcein negative cells were considered dead (absence of green).
2.8

Fluorometric Activity Assay for Cathepsin B
After growing the cultures at pH 7.4 or 6.8, cathepsin B activity (active and

latent) in MDA-MB-231 cell lysates and conditioned media was assessed using
Z-Arg-Arg-NHMec, a selective cathepsin B substrate, as previously described
(Cavallo-Medved et al., 2009). To measure intracellular and membrane bound
cathepsin B activity, 50 µl of sample was treated with 300 µl of activator buffer (5
mM EDTA, 10 mM DTT, pH 5.2) for 15 min at 37 °C. Endogenous inhibitors
secreted by the cell inhibit active cathepsin B in the media, but latent or
procathepsin B activity can be measured by exposing the active site of
procathepsin B in the presence of negatively charged dextran sulfate (Caglic et
al., 2007). Briefly, 50 µl of conditioned media was mixed with 300 µl of citrate
buffer (20 mM citrate buffer, pH 4.6, 10 mM DTT and 25 µg/ml dextran sulfate)
and incubated for 45 min at 37 °C, then added in triplicate to a 96-well flat-bottom
black microtiter plate. For cell lysates 100 µl of cell lysate/activator buffer mixture
were added to 200 µl of appropriate assay buffer containing 50 µM Z-Arg-ArgNHMec and fluorescence was measured at one-minute intervals for 30 minutes
using a Tecan SpectraFluor Plus plate-reader at an excitation of 360 nm and an
emission of 465 nm and activity was reported as picomoles of NHMec formed per
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min per µg DNA. The highly selective cathepsin B inhibitor CA074 (10 µM) was
used to confirm the specificity of the assay (Murata et al., 1991).
2.9 Immunoprecipitation of ABP-bound cysteine cathepsins
MDA-MB-231 cells were grown in 3D rBM overlay cultures and the day
before collection media were changed to serum-free with the addition of 1 µmol/L
GB123. On the next day, after washing with PBS and sitting in complete media
for an hour, cell lysates were collected in ice-cold RIPA buffer (50 mM Tris HCl,
pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% deoxycholate, and 0.1% SDS). Antirabbit cathepsin B (1:500), anti-rabbit pre-immune IgG (1:500), normal goat
serum (NGS) (1:250), anti-rabbit cathepsin S (1:250), and anti-rabbit cathepsin L
(1:250) were individually added and mixed at 4 ˚C overnight. Alternatively, serial
immunopreciptaitons were performed using anti-rabbit cathepsin B (1:500), antirabbit cathepsin L (1:250), and anti-goat cathepsin S (1:40). Pierce Protein A/G
Plus Agarose beads (30 µl) were then added and mixed overnight at 4 ˚C and an
additional 30 min at room temperature. Supernatants and beads collected; the
beads were washed with RIPA buffer and boiled after addition of 2X sample
buffer (20% glycerol, 100 mM Tris HCl, pH 6.8, 6% SDS, and 10% betamercaptoethanol). Acetone at 0 ˚C was added to the supernatant, and the
mixture kept at –80 ˚C for 2 h, centrifuged at 14,000 × g at 4˚C for 30 min, and
the pellet air dried at room temperature and dissolved by boiling in sample buffer.
Immunoprecipitated proteins were collected by centrifugation at 14,000 × g at
4˚C for 30 min, air dried at room temperature and dissolved by boiling in sample
buffer. Immunoprecipitated proteins and supernatants were separated on 12%
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SDS-PAGE and the gels visualized using a CCD camera-equipped Bio-Rad
Versadoc 5000MP imager (excitation/emission 633/680 nm).
2.10

Animals
Mice were housed according to IACUC protocol at the University of South

Florida vivarium located within the H. Lee Moffitt Cancer Center (Tampa, FL). 46 week old female SCID-beige mice (Charles River) were used for fluorescent
imaging of orthotopic tumors.
2.11 In vivo imaging of active cysteine cathepsins
SCID mice (n=7) were separated into two cohorts prior to cell injection and
were provided either tap (n=3) or 400 mM sodium bicarbonate (n=4) drinking
water. In preparation for injection, the MDA-MB-231 cells were trypsinized and
washed once with PBS. Cells were resuspended at a concentration of 1 x 107
cells/ 100 µL in a 1:1 mixture of PBS and Matrigel and injected into the right,
number four mammary fat pad of each mouse.

Tumors were monitored by

caliper measurements, and when tumors reached ~400 mm3, animals were
imaged.

18 hours prior to imaging, 25 nmols of GB123 was injected

intravenously into mice (Blum et al., 2005). In vivo measurements were obtained
using an Optix-MX3 (Advance Research Technologies, a subsidiary of SoftScan
Healthcare Group, Montreal, Canada). Fluorescent images were acquired using
a 670-nm pulsed laser diode and a scan resolution of 1.5 mm. Images were
analyzed using Optix-MX3 Optiview Software.
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2.12 Immunohistochemistry of orthotopic tumors
Pimonidazole HCl (60 mg/kg; Hypoxyprobe) was injected into the
peritoneal cavity one hour prior to tumor removal. MDA-MB-231-RFP tumors
were formalin fixed and paraffin embedded (FFPE) for immunohistochemcal
analysis.

FFPE cross-sections were stained with rabbit anti-sera against

pimonidazole HCl followed by Ventana OmniMap anti-rabbit HRP secondary.
The detection system used was the Ventana ChromoMap Kit and slides were
then counterstained with hematoxylin. Processed slides were scanned using the
Aperio™ (Vista, CA) ScanScope XT with a 200x/0.8NA objective lens at a rate of
5 minutes per slide via Basler tri-linear-array.
Pimonidazole HCl was used to identify hypoxic areas. However, it does
not stain necrotic tissue due to the lack of viable cells, although likely hypoxic.
To segment viable and non-viable tissue, an optimized Aperio Genie® v1
customized histology pattern recognition algorithm was developed to distinguish
between tissue types based on various morphologies.

The algorithm was

applied to the entire slide’s digital image to determine the percentage of each
tissue type (viable or non-viable) by area (µm2).
pimonidazole

HCl

in

viable

tissue

was

Intensity analysis of

performed

using

an

Aperio

PositivePixelCount® v9.0 algorithm with the following optimized thresholds
[HueValue=0.1;

HueWidth=0.5;

Iwp(High)=220;

Iwp(Low)/Ip

(High)=175;

Ip(Low)/Isp (High)=100; Isp(Low)=0; Inp(High)=-1] to segment positive pixels of
various intensities. The percentage of positivity was quantified by the number of
cells exhibiting positive stain as a percentage of total viable tumor cell count. The
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staining intensity can be thresholded into negative (0), low (1+), moderate (2+)
and strong positive (3+) by mean stain density (0-255 dynamic range) for each
tumor cross section.

Positive pixel analysis was completed using Spectrum

(Aperio Technologies).
2.13

RNA isolation for microarray [adapted from (Wojtkowiak et al., 2012)]
Three-dimensional cultures were established of ~4.5 x 105 cells each for

MCF10A, MCF10.DCIS, SUM102, SUM225 and N1ME cell lines. Cells were
seeded on 100-mm plates coated with solidified Cultrex. WS-12Ti fibroblasts
(~4.5x105) were seeded in duplicate on 100 mm plates coated with collagen I.
The cells were then overlaid with 2% rBM diluted in growth media as specified
above and media were changed on day four. On day eight, media were switched
to pH buffered DMEM/F12 containing 2% rBM for an additional incubation of 72
hours. All cells, with the exception of the WS-12Ti fibroblasts, were harvested for
RNA isolation in cold PBS with 5 mM EDTA. The WS-12Ti fibroblasts were
harvested with 0.1% collagenase. RNA was isolated using an RNeasy Mini kit as
described in manufacturer’s protocol from QIAGEN (Valencia, CA). Total RNA
quality was assessed and determined to be high quality as demonstrated by the
absence of degradation products rRNA banding from the 26 and 19S.
2.14

Microarray pathway analysis using biocomputational software
One technical replicate for each of the 12 conditions (six cell lines at both

neutral and acidic pHe) described above (2.13) was applied to Affymetrix HGU133 plus two Arrays (AffyMetrix®; Santa Clara, CA). Gene expression in the six
cell lines (MCF10A, MCF10.DCIS, SUM 102, SUM 225, N1ME, and WS-12Ti) at
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pHe 6.8 or 7.4. was determined at the H. Lee Moffitt Cancer Center and
Research Institute, Florida. Commonalities among the six cell lines in gene
expression changes induced by exposure to an acidic pHe were analyzed using:
1) GeneGo MetaCore pathway analysis software (www.genego.com, St. Joseph,
MI) at the Moffitt Cancer Center and 2) Genomatix (Genomatix Software GmbH,
Munich, Germany) at the C.S. Mott Center for Human Growth & Development at
Wayne State University.
A more thorough approach for bioinformatics analysis was designed in
collaboration with the KCI Systems and Computational Biology core.

The

original data from the Affymetrix HG-U133 plus two Arrays was used to perform
the analysis. CEL files were used in a pair wise (pH 6.8 and pH 7.4) manner in
GeneSpring (Agilent Technologies, Inc., Santa Clara, CA) to make normalized
probe-level and gene-level experiments. SScore [(Kennedy et al., 2006) package
http://home.att.net/~richard-kennedy/professional.html]

was

used

to

find

differentially expressed probes from pair-wise (pH 6.8 and pH 7.4) CEL files at
the significance=3.0 level (two-tailed p-value=0.003). Probe-level experiments
and R scripts (written by core group using R–R64- R.app GUI 1.34 (5589)
x86_64-apple-darwin9.8.0) were used to perform quality analysis generating
histograms and probe data files. Gene-level experiments generated full fold
change files for the SScore probe lists and Venn diagrams and subsequently for
making IPA Entrez gene ID uploads.

BioVenn (Hulsen et al., 2008)

(http://www.cmbi.ru.nl/cdd/biovenn/) was used for comparisons of the three DCIS
cell lines. Using an SScore of 3, we identified 102 significantly changed Entrez
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gene ids in the areas of overlap among the three DCIS cell lines. The commonly
grouped gene lists were examined with Ingenuity Pathway Analysis (IPA) core
analysis software (Redwood City, CA).
2.15

Statistical Analysis
Except where otherwise described, all experiments were analyzed using a

two-tailed, unpaired Student’s T-test to determine statistical significance.

	
  

	
  

43	
  

CHAPTER 3
CONTRIBUTION OF CYSTEINE CATHEPSINS,
INCLUDING CATHEPSIN B, TO PROTEOLYSIS
3.1

Introduction
Reprogramming of energy metabolism is one of two emerging cancer

hallmarks recently added to the original six hallmarks of cancer (Hanahan and
Weinberg, 2000; Hanahan and Weinberg, 2011).

Byproducts of elevated

glycolytic activity result in an acidic extracellular pH (pHe) that is both
heterogeneous and dynamic in solid tumors [for review, see (Gillies et al., 2002)].
Many cancer cells acquire acid-resistant phenotypes that allow them to survive
and proliferate when the pHe is acidic (Gatenby et al., 2007; Wojtkowiak et al.,
2012) (Figure 1.4). Acidification of the tumor microenvironment has been shown
to increase invasiveness and metastasis.

The acid-mediated invasion

hypothesis has been further described in chapter 1.4.
One type of solid tumor that has an acidic pHe phenotype is breast
cancer. Breast cancer is a well-studied disease, but the diverse characteristics
of the disease as a whole make it very complex and many challenges remain.
The cell lines typically used can be genetically sub-categorized to allow one to
delineate the diverse characteristics of primary tumors (Neve et al., 2006). The
molecular characteristics correspond to morphological characteristics observed
by imaging cultures grown in 2D (Han et al., 2009) or 3D (Han et al., 2010;
Kenny et al., 2007).

	
  

Clinically, triple negative breast cancer (TNBC) is
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characterized by the lack of estrogen receptor (ER), progesterone receptor (PR)
and (human epidermal growth factor receptor 2 (HER-2). TNBC is the most
difficult to treat because of the lack of targeted treatment options. At present
TNBC is treated with chemotherapeutics and responses to those varies greatly
among patients. TNBC has a shorter time to relapse and death and
disproportionally affects African American women and younger women (for
reviews of TNBC, see (Hudis and Gianni, 2011; Irvin and Carey, 2008)). TNBC
can be further sub-categorized into two basal-like (BL1 and BL2), an
immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL),
and a luminal androgen receptor (LAR) subtypes. Comparative studies of these
subtypes may help to design rational drug treatment strategies (Lehmann et al.,
2011). I chose to focus my study on the most invasive types of breast cancer the
TNBC MSL subtype. The MDA-MB-231 cells in 3D rBM overlay culture exhibit a
stellate morphology characteristic of aggressive motile cancers (Han et al.,
2010). MDA-MB-231 cells are the most commonly studied in this subtype of
TNBC and thus would be a good cell line for comparison with the previous
protease work in cells cultured at a neutral pH. Using MDA-MB-231 xenografts,
we buffered systemic and intratumoral pH in mice and showed that these
treatments reduced spontaneous metastasis (Robey et al., 2009). The systemic
elevation in pHe is thought to reduce the activity of proteases that have an acidic
pH optimum, such as cysteine cathepsins.
Proteases, including cathepsin B, have been implicated in every stage of
cancer progression from initiation and growth to metastasis (Edwards et al.,
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2008). In order for a cancer cell to migrate away from the primary site, it has
long been recognized that the basement membrane and extracellular matrix
requires proteolytic modification. Cysteine cathepsins participate in proteolytic
networks that mediate cancer progression [for reviews, see (Mohamed and
Sloane, 2006; Rothberg et al., 2012)]. As in vitro tissue culture experiments have
been conducted at neutral pH, we now hypothesize that such analyses may have
overemphasized the role of proteases that have neutral pH optima, such as the
MMPs. The acidic tumor microenvironment would favor the activity of proteases
such as cysteine cathepsins that normally function at lysosomal pH, leading us to
re-examine proteolysis and the proteases that are released and active at the
acidic pHe surrounding solid tumors. For these studies, we used a 3D rBM
overlay model that provides a context for mechanisms critical to both mammary
gland development and neoplastic processes, as has been described [for
reviews, see (Debnath and Brugge, 2005; Weigelt and Bissell, 2008) also see
chapter 1.3]. We are building on previous studies that have shown that an acidic
pHe leads to lysosomal redistribution and secretion of cathepsin B in malignant
cells (Rozhin et al., 1994).

Our study suggests that cathepsin B is active

pericellularly and is one of the proteases that participates in the enhanced
degradation of collagen IV observed at an acidic pHe.
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Results

3.2.1 Live-cell imaging of 3D rBM overlay cultures confirms presence of active
proteases and proteolysis.
To test our hypothesis that an acidic pHe enhances proteolytic activity and
degradation of the basement membrane, we grew MDA-MB-231 in 3D rBM
overlay cultures, following our previously described methods (Sameni et al.,
2012). A quenched fluorescent form of the basement membrane protein type-IV
collagen, i.e., DQ-collagen IV, was used to detect general proteolysis. The
activity-based probe (ABP) GB123, which covalently binds to the active site
(Blum et al., 2005), was used to detect active cysteine cathepsins. We illustrate
in Figure 2.3 live-cell imaging of degradation products of DQ-collagen-IV (A, C)
and labeling of active cysteine cathepsins with GB123 (A, D) and nuclei with
Hoescht 33342 (B) in MDA-MB-231 3D rBM overlay cultures.

We use this

methodology to examine differences in DQ-collagen IV degradation and in active
cysteine cathepsins, including their localization, at an acidic (6.8) as compared to
a neutral (7.4) pHe.
3.2.2 Acidic pHe enhances degradation of collagen IV.
The acidic pHe of 6.8 was chosen as our test condition based on literature
reports of the pHe in breast cancers and xenograft models (Gillies et al., 2002).
In MDA-MB-231 3D rBM overlay cultures, we observed accumulation of
degradation fragments of the basement membrane protein substrate at both pHe
6.8 and 7.4 over a period of 3 days (Figure 3.1). More extensive pericellular
degradation products of DQ-collagen IV were apparent at pHe 6.8 (Figure 3.1,
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right panels). To better illustrate differences in degradation at the acidic pH,
additional perspectives of the upper panels in Figure 3.1 can be viewed in
Supplemental Movies 1 and 2.

This effect was verified in 3D cultures of a

second triple negative breast cancer cell line, Hs578T, and also in HCT116 colon
carcinoma cells. HCT116 cells have previously been shown to acidify the tumor
microenvironment similarly to MDA-MB-231 cells (Estrella et al., 2013).

The

percentage increases in DQ-collagen IV degradation products, normalized to cell
number, at pHe 6.8 for MDA-MB-231, Hs578T and HCT116 3D cultures are
shown in Figure 3.2. There was a significant increase in DQ-collagen IV
degradation products at the acidic pHe for MDA-MB-231 and HCT116 3D
cultures and a trend towards increased DQ-collagen IV degradation products at
the acidic pHe for Hs578T 3D cultures (p=0.10). To rule out a direct effect of
acidic pHe on degradation of DQ-collagen IV, coverslips coated with rBM were
incubated as above, but without cells; there were no observable degradation
products present at either acidic or neutral pH (Figure 3.3).
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A

B

C

D

E

F

Figure 3.1. Degradation of DQ-collagen IV was greater at an acidic pHe. Left
Figure 3.1
(A, C and E) and right (B, D and F) panels depict 3-day cultures of MDA-MB-231
cells grown in 3D rBM overlay cultures at pHe 7.4 and 6.8, respectively. A and B
represent the entire 3D volume showing cells (red), degradation products of DQcollagen IV (green) and nuclei (blue). C and D represent degradation products of
DQ-collagen IV in the entire 3D volume. E and F represent intensity maps of the
degradation products in C and D (white, most intense; violet, least intense).
Images depicted represent the average fluorescent intensity of DQ-collagen IV
degradation products per cell obtained in 14 to 15 images at the two pHs; bar,
22.6 µm
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Figure 3.2. Quantification of DQ-collagen IV degradation products on a per
cell basis for MDA-MB-231, Hs578T and HCT116 3D rBM overlay cultures.
Figure'3.2'
Values represent % increase at pHe 6.8 ( ) over pHe 7.4 controls (0% ± s.e.m);
n ≥ 3 independent experiments with an average of 17 images analyzed per
condition; ***, p ≤ 0.001.
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pH 7.4

pH 6.8

Figure 3.3.
In the absence of cells, degradation products (green
fluorescence) could not be observed at either pHe 7.4 or 6.8.

3.2.3 Human carcinoma cells exhibit an acid-resistant phenotype in 3D rBM
overlay culture.
To exclude possible effects of acidic pHe on proteolysis due to differences
in proliferation and viability, we analyzed 3D rBM overlay cultures of the MDAMB-231, Hs578T, and HCT116 carcinoma cells for an acid-resistant phenotype.
We did not observe any differences in proliferation, as assessed by Click-IT®
EdU and MTT assays. Nor was there a change in cellular viability as measured
13'
by a live/dead assay. Data are shown for MDA-MB-231 cells in Figure 3.4. Thus

Figure 3.3

under the conditions of our cultures, we establish that the MDA-MB-231, Hs578T
(data not shown) and HCT116 (data not shown) carcinoma cells have an acidresistant phenotype.
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Figure 3.4. MDA-MB-231 cells in 3D rBM overlay cultures exhibited similar
proliferation and viability at pHe 7.4 (white bar) and 6.8 (gray bar),
indicating an acid-resistant phenotype. Proliferation was assessed by two
methodologies: A) EDU incorporation and B) MTT assays. Viability was
assessed by: C) live/dead assays. All data represent mean ± s.e.m.; n ≥ 3
independent experiments performed in triplicate; p ≥ 0.05.

Figure 3.4
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3.2.4 Acidic pHe increases pro and active cathepsin B.
Previous studies on 2D cultures have demonstrated that an acidic pHe
results in a peripheral distribution of cathepsin B intracellularly as well as
cathepsin B secretion (Rozhin et al., 1994). Similarly, in lysates of MDA-MB-231
cells grown in 3D rBM overlay culture at pHe 6.8, cathepsin B activity was
significantly increased (Figure 3.5 A; p = 0.046). Secretion of procathepsin B
(dextran sulfate-activated) was also significantly increased (p = 0.02), as
assessed by assaying cathepsin B activity in the conditioned media (Figure 3.5
B). Activity was eliminated by CA074, a highly selective cathepsin B inhibitor,
confirming the specificity of the assay for cathepsin B (Murata et al., 1991).
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Figure 3.5. Cathepsin B activity was increased at acidic pHe. MDA-MB-231
cells were grown in 3D rBM overlay cultures at pHe 7.4 or 6.8 and then serum
starved (0.2% FBS) for 24 hours in media buffered at either pH 7.4 or 6.8. Cell
lysates (A) and conditioned media (B) were analyzed for activity of cathepsin B
and dextran sulfate activated pro-cathepsin B respectively, using, Z-Arg-ArgNHMEC. Activity was completely abrogated by 10 µM CA074 (I) versus vehicle
control (V), thus confirming the specificity of the assay. Data were normalized to
DNA and are scaled to activity at pH 7.4, designated as 100%; *, p ≤ 0.05.

Figure 3.5
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3.2.5 Inhibition of cathepsin B decreases degradation of collagen-IV.
To determine whether increased cathepsin B activity at pHe 6.8
contributed to the enhanced degradation of DQ-collagen IV (Figure 3.1), we
tested the ability of CA074, a highly selective cathepsin B inhibitor (Murata et al.,
1991), to affect that degradation. At both pHe 7.4 and 6.8, inhibition of cathepsin
B reduced the accumulation of degradation fragments of DQ-collagen IV (Figure
3.6; also see Supplemental Movies 3 - 6). Proteolysis was significantly reduced,
but not completely abrogated, by CA074 at both pHe 7.4 (Fig. 4E; p = 0.004) and
6.8 (Fig. 4F; p = 1E-7). The reduction in proteolysis at pHe 6.8 was 12% greater
than at pHe 7.4, consistent with cathepsin B contributing to the enhanced
degradation of DQ-collagen IV at pH 6.8. The reduction in proteolysis in the
presence of 20 µM CA074 was not due to cell death, as assessed by a live-dead
assay (Figure 3.7). Our results suggest that cathepsin B as well as other
proteases contribute to the degradation of the basement membrane protein
collagen IV at both a neutral and acidic pHe.
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Figure 3.6. Degradation of DQ-collagen IV was reduced by inhibition of
cathepsin B. MDA-MB-231 cells (red) were grown at pHe 7.4 (A, C) or 6.8 (B,
D) in 3D rBM overlay cultures in the presence (C, D) or absence (A, B) of CA074.
Degradation products of DQ-collagen IV (green) were present in DMSO vehicle
controls (A, B) and reduced in the presence of the cathepsin B inhibitor (C, D).
Images were chosen as ones representing the average fluorescent intensity of
degradation products of DQ-collagen IV per cell (nuclei, blue); bar, 22.6 µm. DQcollagen IV degradation products were quantified on a per cell basis in the entire
3D volume for pHe 7.4 vehicle (V) and CA074 (I) (E) and 6.8 vehicle (V) and
CA074 (I) (F). Values represent % of DMSO vehicle controls (100% ± s.e.m); n
≥ 3 independent experiments with 13-19 images analyzed per condition; **, p ≤
0.01 and ***, p ≤ 0.001.

A

B

Figure 3.7. Incubation with 20 µM CA074 (B) did not increase cell death as
compared to that observed with DMSO (vehicle control, A) in 3D rBM
overlay cultures of MDA-MB-231-RFP cells (red). A live-dead assay was used
to assess toxicity (absence of green). Tiled images showing 12 fields of view
were captured with a 20X lens; bar, 180 µm.
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3.2.6 At Acidic pHe GB123 is increased pericellularly.
We have shown that we can visualize active cysteine cathepsins in 3D
rBM overlay cultures of live breast carcinoma cells using ABPs that covalently
bind to the active site of cysteine cathepsins B, L and S (e.g., see Figure 2.3).
We observed a significant increase in bound GB123 at pHe 6.8 (cf. left with right
images in Figures 3.8, 3.9, and 3.10, upper panels). In normal cells, cysteine
cathepsins are localized intracellularly in lysosomes; however, in tumor cells
some cysteine cathepsins, e.g. cathepsin B, are lysosomal, secreted and bound
to the cells surface (Mohamed and Sloane, 2006). We have previously shown
that an acidic pHe increases the secretion and cell surface association of
cathepsin B in malignant cells grown in monolayer culture (Rozhin et al., 1994).
Here we determined whether pHe 6.8 altered distribution of cysteine cathepsins
in our 3D rBM overlay cultures. We used image arithmetic in MetaMorph™, as
described previously (Jedeszko et al., 2008), to quantify intracellular and
extracellular fluorescence of bound GB123. There was a significant increase in
GB123 bound (i.e., active cysteine cathepsins) pericellularly at pHe 6.8 (cf.
middle panels Figures 3.8, 3.9, and 3.10).
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Figure 3.8. Total and pericellular active cysteine cathepsins in 3D rBM
overlay cultures of MDA-MB-231 breast carcinoma cells were increased at
pHe 6.8. Active cysteine cathepsins were labeled, using GB123 (cyan), in the
Figure
3.8of 3D rBM overlay cultures of MDA-MB-231 cells (red) grown at pH
entire
volume
7.4 (left panels) and pH 6.8 (right panels). The amount of total bound GB123 is
shown in upper panels (A, B), pericellular bound GB123 in the middle panels (C,
D) and intracellular bound GB123 in the bottom panels (E, F). Images depicted
represent the average fluorescent intensity of bound GB123 per cell; bar, 22.6
µm. G) Graphs depict average fluorescent intensity of bound GB123 per cell ±
s.e.m at pHe 7.4 ( ) and 6.8 ( ); n ≥ 3 independent experiments with an
average of 26 images analyzed per condition; **, p ≤ 0.01 and ***, p ≤ 0.001.
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Figure 3.9. Total and pericellular active cysteine cathepsins in 3D rBM
overlay cultures of Hs578T breast carcinoma cells were increased at pHe
6.8. Figure
Active 3.9
cysteine cathepsins were labeled, using GB123 (cyan), in the entire
volume of 3D rBM overlay cultures of Hs578T cells (red) grown at pH 7.4 (left
panels) and pH 6.8 (right panels). The amount of total bound GB123 is shown in
upper panels (A, B), pericellular bound GB123 in the middle panels (C, D) and
intracellular bound GB123 in the bottom panels (E, F). Images depicted
represent the average fluorescent intensity of bound GB123 per cell; bar, 22.6
µm. G) Graphs depict average fluorescent intensity of bound GB123 per cell ±
s.e.m at pHe 7.4 ( ) and 6.8 ( ); n ≥ 3 independent experiments with an
average of 12 images analyzed per condition; ***, p ≤ 0.001.
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Figure 3.10 Total and pericellular active cysteine cathepsins in 3D rBM
Figure
3.10 of HCT116 colon carcinoma cells were increased at pHe
overlay
cultures
6.8. Active cysteine cathepsins were labeled, using GB123 (cyan), in the entire
volume of 3D rBM overlay cultures of HCT116 cells (red) grown at pH 7.4 (left
panels) and pH 6.8 (right panels). The amount of total bound GB123 is shown in
upper panels (A, B), pericellular bound GB123 in the middle panels (C, D) and
intracellular bound GB123 in the bottom panels (E, F). Images depicted
represent the average fluorescent intensity of bound GB123 per cell; bar, 22.6
µm. E) Graphs depict average fluorescent intensity of bound GB123 per cell ±
s.e.m at pHe 7.4 ( ) and 6.8 ( ); n ≥ 3 independent experiments with 17
images analyzed per condition; **, p ≤ 0.01 and ***, p ≤ 0.001.
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As this is, to our knowledge, the first time that GB123 has been used to

detect active cysteine cathepsins pericellularly, we employed the broad-spectrum
cysteine protease inhibitor, E64, to confirm that the bound GB123 was detecting
active cysteine proteases pericellularly.

At pHe 6.8 we again observed

significantly greater total and pericellular bound GB123 (cf. Fig. 3.11B with Fig.
3.11A). Pericellular bound GB123 was adjacent to the cells, consistent with the
known membrane association of cysteine cathepsins in tumors (Mohamed and
Sloane, 2006) and with the removal of active non-cell associated cysteine
cathepsins bound to GB123 by washing. The increase in bound GB123 at pHe
6.8 was reduced by E64, confirming that GB123 was detecting active cysteine
proteases. To determine which of the cysteine cathepsins known to be detected
by GB123 (Blum et al., 2005) were present in our 3D rBM overlay cultures, we
subjected cell lysates to immunoprecipitation using antibodies to cathepsins B, L
and S. We detected binding of GB123 to cathepsin B and cathepsin L, but were
unable to detect binding of GB123 to cathepsin S (Figure 3.12). To confirm an
absence of cathepsin S, serial immunoprecipitations (Figures 3.13 and 3.14)
were performed using a different cathepsin S antibody. A signals were observed
at about 31-kDa, the molecular weight as cathepsin B, rather than 28-kDa as
expected for active cathepsin S (Figures 3.13 and 3.14). These results would be
consistent with the active cysteine cathepsins detected by GB123 in the 3D
cultures at an acidic pHe being cathepsins B and L.
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Figure 3.11. Pericellular bound GB123 was reduced by E64, a broadspectrumFigure
inhibitor
6 of cysteine proteases. Active cysteine cathepsins were
labeled, using GB123 (cyan), in the entire 3D volumes of 3D rBM overlay
cultures of MDA-MB-231 cells (red) grown at pHe 7.4 (A, C) or 6.8 (B, D). Upper
(A, B) and lower (C, D) images represent vehicle (DMSO) controls and E64,
respectively. Images depicted represent the average intensity of pericellular
bound GB123/cell; bar, 22.6 µm. E) Graph illustrates average integrated
intensity ± s.e.m of total, pericellular and intracellular bound GB123 at pHe 7.4
vehicle ( ) and E64 ( ) and pHe 6.8 vehicle ( ) and E64 ( ); n ≥ 3
independent experiments with an average of 19 images analyzed per condition.
Analysis of variance was used to determine significance; ***, p ≤ 0.001.
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Figure 3.12. Active cysteine cathepsins in MDA-MB-231 cells were profiled
by in-gel fluorescence with the ABP GB123. Signals for GB123-bound
cathepsin B and L were identified by immunoprecipitation. Signals are
shown pseudocolored in red to represent the far-red emission of Cy5 (top panel)
and in an inverted gray scale (bottom panel). Signals represent covalent binding
of GB123 to the active site of cysteine cathepsins in lysates of 3D rBM overlay
cultures of the MDA-MB-231 cells.
Lanes represent: supernatants after
immunoprecipitation with either preimmune IgG (lane 2) or antibodies to
cathepsin B (lane 4), S (lane 6) or L (lane 8) or pellets after immunoprecipitation
with either preimmune IgG (lane 3) or antibodies to cathepsin B (lane 5), S (lane
7) or L (lane
9); or molecular weight markers (lanes 1 and 10).
Figure
3.12
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Figure 3.13. Active cysteine cathepsins B and L in MDA-MB-231 cells were
identified by sequential immunoprecipitation with antibodies to cathepsins
L, B and S. Signals represent GB123-bound active cysteine cathepsins in
lysates of 3D rBM overlay cultures of the MDA-MB-231 cells. Lanes represent
total cell lysate (lane 2), supernatant after serial immunoprecipitation with
antibodies to cathepsin L, B and S (lane 6) and pellet after immunoprecipitation
with antibodies to cathepsin L (lane 3), B (lane 4) or S (lane 5); or molecular
weight markers (lanes 1 and 7).

Figure 3.13
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Figure 3.14. Absence of GB123-bound cathepsin S in MDA-MB-231 cells
was confirmed by sequential Immunoprecipitation with antibodies to
cathepsins S, B and L. Signals represent covalent binding of GB123 to the
active site of cysteine cathepsins. Lanes represent supernatants after
immunoprecipitation with normal goat serum (lane 2) or preimmune IgG (lane 4)
or after serial immunoprecipitation with antibodies to cathepsin S, B and L (lane
9); pellets after immunoprecipitation with normal goat serum (lane 3), preimmune
IgG (lane 5) or antibodies to cathepsin S (lane 6), B (lane 7) or L (lane 8); or
molecular weight markers (lanes 1 and 10).

Figure 3.14
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3.2.7 GB123 is detected in tumors in vivo
Our previous studies have show that, without affecting systemic pH,
imbibement of sodium bicarbonate is able to neutralize intertumoral pHe and
reduce spontaneous metastasis (Robey et al., 2009). To test our hypothesis that
the acidic tumor microenvironment enhances cysteine cathepsin activity in vivo,
we measured GB123 intensity values in acidic or bicarbonate neutralized
orthotopic MDA-MB-231 tumors (Figures 3.15 and 3.16A). The cohort sample
was small and in addition one of the tumors in a bicarbonate treated mouse
became severely ulcerated and could not be used for this analysis. Nonetheless
despite the small sample size, there was a significant decrease in bound GB123
with sodium bicarbonate imbibement (Figure 3.16B).

Correlating with an

expected more acidic pHe in the control group, There was a decrease in viable
tissue in the control group due to the combination of acidosis and hypoxia (Figure
3.18), whereas there was not a significant change in the amount of hypoxia
(Figure 3.16C and D).

Our results demonstrate the increased activity of

cathepsin B and other cysteine cathepsins in an acidic environment in vitro and
in vivo.
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Figure 3.15. GB123 localizes to orthotopic MDA-MB-231 tumors in vivo,
indicating that active cysteine cathepsins are present in these tumors.
Images 3.15
represent fluorescence of GB123 retained 18 hours post-injection
Figure
overlaid on tumor-bearing mice.

	
  

	
  

68	
  

A

B
Normalized Counts x 106

Bicarbonate

Tap

GB123
8

*
4

-

Tap
1

D
Pimonidazole

Tap

C

Bicarbonate
2

% Positive

Bicarbonate

45

30

15

-

Tap
1

Figure 3.16

	
  

2
Bicarbonate

	
  

69	
  

Figure 3.16. In vivo buffering of tumor pHe reduced tumor binding of
GB123. A) Enlarged representative fluorescent images, from the six shown in
Figure 3.15, of MDA-MB-231 orthotopic tumors showing retention of GB123 18
hours post-injection. B) Average normalized counts of GB123 retained in MDAMB-231 orthotopic tumors ± s.e.m; a one-tailed, unpaired T-test was used to
determine significance, p = 0.03. C) Representative images of positive pixel
analysis of viable stained tissue illustrating intensity of pimonidazole staining:
blue is negative staining, orange is moderate staining, red is strong positive
staining, and gray is non-viable tissue. Inset shows immunohistochemistry of
pimonidazole staining used for analysis. Size markers in both are equal to 1 mm.
D) Quantification of pimonidazole staining in FFPE tumors, reported as number
of strong positive pixels / number of pixels of viable tissue ± s.e.m; p = 0.086.
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Figure 3.17. Segmentation of viable tissue. A) Representative IHC staining of
pimonidazole in orthotopic MDA-MB-231 tumors from mice given tap water or
water containing sodium bicarbonate to drink. B) Computational segmentation of
viable (green) and non-viable tissue (pink). C) Positive pixel analysis of
segmented viable tissue showing intensity of pimonidazole staining: blue
indicates negative staining, orange moderate staining and red strong staining.

Figure 3.17
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3.3 Discussion
The acid-mediated invasion hypothesis is supported by a large quantity of
correlative data described in chapter 1.4. This increase in active proteases may
enhance invasion since in cancer xenografts invasion has been shown to occur
more often in regions where the pHe is acidic (Estrella et al., 2013).

The

possibility that cysteine cathepsins facilitate acid-mediated invasion is supported
by prior work demonstrating that acid pHe induces redistribution of endosomes
and lysosomes to the cell surface and increases release of cysteine cathepsins
(Glunde et al., 2003; Rozhin et al., 1994; Steffan et al., 2009). In MCF10A, a
diploid mammary epithelial cell, exposed to an acidic pH for one hr show a
redistribution of cathepsin B towards the membrane periphery, while the
transformed MFC10neoT cells increased the release of cathepsin B (Rozhin et
al., 1994). Lysosomal movement to cell periphery in response to pHe was also
observed in breast cell lines of varying malignancy including the MDA-MB-231
cells (Glunde et al., 2003). Additionally, this study noted the decrease in number
of lysosomes at the slightly acidic pH of 6.8, suggesting that they might be
exocytosed, such as what is observed with cathepsin B and the more the
malignant cell lines had larger vesicles reminiscent of macroautophagy, although
neither aspect was examined in these studies.
The redistribution of cathepsin B, endosomes, and lysosomes towards the
cell periphery is microtubuial dependent process (Heuser, 1989; Matteoni and
Kreis, 1987; Rozhin et al., 1994). In addition to pH-dependent relocation and
exocytosis, additional roles for lysosomes and the cell periphery have been
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illuminated such as the Ca-dependent exocytosis observed in both non-secretory
cells and as a function of mammalian plasma membrane repair (Andrews, 2002;
Jaiswal et al., 2002; Reddy et al., 2001). Macrophages and fibroblasts also
exhibit redistribution of endosomes and lysosomes towards the cell periphery in
response to slightly acidic pH (Heuser, 1989), suggesting this might be an
universal cellular response, In our study we observed cysteine cathepsins at the
cell periphery and extracellularly in cells cultured at pH 6.8 in two invasive breast
cancer cell lines (Figures 3.8 and 3.9) as well as in a colon carcinoma cell line
(Figure 3.10), and previously in breast, colon, and melanoma cell lines of higher
malignancy (Rozhin et al., 1994) suggesting our results are applicable in other
aggressive solid tumors.
In the current work, we show using selective labeling with ABPs and
inhibitors that cysteine cathepsins, notably cathepsin B, are involved in the acidmediated degradation of the basement membrane protein type-IV collagen,
which is integral to acid-mediated invasion. This study shows for the first time
detection of pericellularly ABP-bound cysteine cathepsins in the highly malignant
cells (Figures 3.8, 3.9, 3.10). This may reflect: 1) the extensive invasive
processes on these cells, processes with a large surface area for the binding of
membrane-associated cysteine cathepsins such as cathepsin B (Mohamed and
Sloane, 2006); 2) the acid resistant-phenotype of these cells; and 3) retention
pericellularly of secreted cysteine cathepsins by the matrix used for the 3D rBM
overlay cultures.
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The exact effects of acidic pHe are still unknown. As the invasive cancer

cells are acid-resistant (Figure 3.5) and can maintain a neutral intracellular pH
even in the face of low pHe, we do not suspect that the response to an acidic
pHe is transduced through a lowering of cytosolic pH. In fact, there are many
studies confirm that the intracellular pH remains in the normal range (Gerweck
and Seetharaman, 1996; Hulikova et al., 2012; McCarty and Whitaker, 2010;
Wojtkowiak et al., 2011; Zhang et al., 2010). Rather we hypothesize that there is
an increase in fusion of secretory lysosomes with the plasma membrane and
release of their contents.

One of the classic examples of cells that contain

secretory lysosomes is the osteoclast (Andrews, 2000).

At the site of bone

degradation, osteoclasts generate resorption lacunae that become highly
acidified (pHe ~ 4.7) via fusion of lysosomes with the plasma membrane. This is
a result of insertion of lysosomal vacuolar H+-ATPases into the plasma
membrane and is accompanied by release of cathepsin K, a cysteine protease
essential for bone degradation (Saftig et al., 1998).

In MDA-MB-231 breast

cancer cells, vacuolar H+-ATPases are highly expressed on the cell surface and
are linked to their invasiveness (Sennoune et al., 2004).
Recently, a number of acid-stimulated ion channels (ASICs) have been
identified, which can transduce acidic pHe through IP3/PI3K pathways and
increase calcium and cAMP signaling (Brown and Wagner, 2012; Chu et al.,
2011). Interestingly, metastatic cancer-associated bone pain, including in breast
cancer, has been linked to signaling through ASICs; in this case the ASICs are
on neurons that innervate bone and respond to the acidic pHe produced by
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osteoclasts involved in bone resorption by the metastatic cancer cells (Yoneda et
al., 2011).

ASICs are part of the superfamily of ENaC/degenerin cation

channels.

ASICs and ENaCs are regulated by proteolysis, including by

membrane anchored serine proteases (Clark et al., 2010; Kota et al., 2012).
ENaCs are also regulated by cysteine cathepsins, specifically by cathepsins B
and S (Alli et al., 2012; Haerteis et al., 2012). Neither regulation of ASICs by
cysteine cathepsins or regulation of both ENaCs and ASICs by cysteine
cathepsins has been studied in cancer cells to our knowledge. Additionally, MSL
subtypes of TNBC have an enrichment of calcium signaling and RHO canonical
pathways (Lehmann et al., 2011).

Cardelli and colleagues have shown in

prostate cancer cells that an acidic pHe initiates lysosomal trafficking to the
plasma membrane, cathepsin B secretion and increased invasion dependent on
microtubules, RhoA and PI3K (Steffan et al., 2009). Based on this series of
observations and the current work, we propose a model wherein extracellular
acidosis is transduced via ASICs into a signal impinging on the PI3K pathway,
microtubules and RhoA to promote the redistribution of lysosomes leading to the
release of cathepsin B and other proteases at the acidic and invasive edges of
the tumors.
In accordance with the acid-mediated invasion hypothesis, the present
study and other studies have shown that an acidic pHe increases expression and
activity of matrix-degrading proteases such as the cysteine cathepsins B and L
and MMP-2 and -9 (Rothberg et al., 2012).

Cathepsin B secreted through

microvesicles or exosomes has (Cavanaugh et al., 1983) been reported at acidic
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pHe to induce greater activation of latent MMPs and to potentiate endothelial cell
invasion and angiogenesis (Giusti et al., 2008; Taraboletti et al., 2006). In the
current study, we have shown a dramatic increase in general proteolysis at acidic
pHe (Figures 3.2 and 3.3), consistent with participation of multiple proteases in
the proteolysis at the acidic pHe.

Resistance of tumor cells weakly basic

chemotherapeutics is increased in vitro by an acidic pHe (Jahde et al., 1990) and
the effectiveness of chemotherapy in mouse models is reduced by the cysteine
cathepsins B and S secreted by tumor-associated macrophages (Shree et al.,
2011). These studies suggest that chemotherapy in combination with an agent
that increases pHe and thereby indirectly reduces cysteine cathepsin activity or
one that directly inhibits cysteine cathepsin activity could be beneficial in the
clinic. Indeed, we have shown in mouse models that tap water supplemented
with sodium bicarbonate, a systemic alkalizing buffer that increases pHe,
decreases metastasis (Robey et al., 2009) and improves response to
chemotherapy (Raghunand et al., 1999).

Sodium bicarbonate treatments to

neutralize the acidic pHe have been investigated in phase I/IIa trials for bone
pain (NCT01350583) and in combination with gemcitabine for unresectable
pancreatic cancer (NCT01198821). Both of these trials have closed, and are
scheduled to re-open as new trials pending reformulation (RJ Gillies, personal
communication).
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CHAPTER 4
ELEVATED STAT1 SIGNALING IN DCIS CELL LINES
REVEALED BY MICROARRAY ANALYSIS
4.1 Introduction
Breast cancer continues to be the most commonly diagnosed cancer in
women. In 2012, 29% of all new cancer diagnoses were breast cancer. The
disease has a high mortality rate (14%), second only to lung cancer (26%). The
American Cancer Society also predicts that, in addition to the 230,480 new cases
of breast cancer, an additional 57,650 new diagnoses of ductal carcinoma in situ
(DCIS) for 2011.

We are interested in forces including those in the

microenvironment that drive breast cancer progression from normal to premalignant to invasive.
Breast cancer remains the most commonly diagnosed cancer in women
(30% or 230,480 new cases predicted for 2011) and has a high mortality rate,
second only to lung cancer. The American Cancer Society predicted that in
addition to the 230,480 new cases of breast cancer there would be 57,650 new
diagnoses of DCIS predicted for 2011.

DCIS incidence has dramatically

increased, mostly but not solely due to advances in standard mammographic
screening. DCIS accounts for 20% of newly diagnosed breast cancer today. A
DCIS diagnosis can range from a non-invasive low-grade lesion to a high-grade
comedo type, which is associated with increased risk for subsequent
development of invasive cancer (Miller et al., 2001). A recent study shows that
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women with DCIS who have reoccurrence of invasive cancer after lumpectomy in
the ipsilateral breast are at an increased risk of mortality, which can be
significantly reduced by adjuvant radiation and tamoxifen (Wapnir et al., 2011).
This increased risk of mortality unfortunately translates into overtreatment for the
95% of women diagnosed with DCIS whose disease will most likely not progress.
Our laboratory has a long-standing interest in the contribution of the tumor
microenvironment to the progression of breast cancer (Moin et al., 2012;
Rothberg et al., 2012; Sloane et al., 2005). There are many aspects of the
breast tumor microenvironment to consider such as surrounding stromal cells
(e.g., fibroblasts and macrophages), normal non-transformed epithelial cells, as
well as non-cellular aspects such as the matrix composition and pH. Previous
studies in our laboratory as well as studies by others indicate that tumorassociated fibroblasts increase proteolysis and invasive characteristics of breast
tumor cells (Moin et al., 2012; Rothberg et al., 2012; Sameni et al., 2009; Sameni
et al., 2003), whereas the myoepithelial cells decrease the invasive
characteristics of the breast cancer cells (Barsky and Karlin, 2006; Holliday et al.,
2009; Hu et al., 2008; Pandey et al., 2010). Our collaborator Dr. Robert J. Gillies
and his group at the Moffitt Cancer Center have a long-standing interest in
understanding the effects of an acidic extracellular microenvironment [for reviews
see (Gillies et al., 2002; van Sluis et al., 1999; Wojtkowiak et al., 2011)].

In a

joint effort with the Gillies laboratory, we are trying to isolate markers that can
identify an acidic pHe as a result of the actively metabolizing DCIS lesions. Our
hypothesis is that the breast microenvironment cells will have a common
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response to an acidic pHe and lead to the progression of DCIS pre-invasive
lesions, i.e., cancer poised to become invasive (Figure 1.5). As there are not at
present any selective biomarkers for an acidic tumor microenvironment,
surrogate biomarkers are used such as carbonic anhydrase, pimonidazole and/or
GLUT1 (Wojtkowiak et al., 2012). Carbonic anhydrase and pimonidazole are
commonly used markers for hypoxia/acidosis and GLUT1 is used as a marker of
a high glycolytic phenotype. In addition to discovering biomarkers for an acidic
pHe, we hope to identify pathways by which an acidic pHe may influence DCIS
progression to invasive carcinoma.
Our laboratory has a variety of breast cell lines (Figure 2.1). The MCF10A
progression series is a human breast model cellular system developed by Dr.
Fred Miller of Karmanos.

The MCF10A is a diploid line that spontaneously

immortalized from a population of cell isolates from a patient with fibrocystic
breast disease who underwent a reduction mammoplasty (Soule et al., 1990). A
series of isogenic cell lines have been derived after serial passaging in vivo of
10A cells with a stable transfection of T24 H-Ras (Dawson et al., 1996; Miller et
al., 1993). The isogenic cell lines (10A, AT1, AT3B, DCIS, and Ca1D) represent
normal, non-invasive, pre-invasive, and invasive phenotypes in vivo (Miller et al.,
2000; Miller et al., 2001; Santner et al., 2001) and our laboratory has
demonstrated these phenotypes in 3D cultures ((Sameni et al., 2009) and
reviewed in (Sameni et al., 2013)). Both SUM-102 and -225 are patient-derived
DCIS cell lines that were established in the Ethier laboratory [(Forozan et al.,
1999; Sartor et al., 1997) and (S. Ethier, MUSC, personal communication)].
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SUM102 has low take rate efficiency (less than half) in establishing palpable
tumors in immunodeficient mouse models. This can be enhanced if the SUM102
cells are mixed with tumor-associated fibroblasts before implantation (Eck et al.,
2009). The MCF10.DCIS line is pre-invasive, yet more than half of xenografts
progress to invasive carcinomas after 9 weeks in vivo (Miller et al., 2000). The
SUM225 line has DCIS characteristics, but is actually a chest wall re-occurrence
from a breast carcinoma (Behbod et al., 2009; Neve et al., 2006; Yang et al.,
2004). The myoepithelial cell line, N1ME, is derived from primary human breast
myoepithelial cells that were immortalized by transduction with MSCV-purohTERT (Hu et al., 2008) and K. Polyak, Dana Farber, personal communication).
WS-12Ti is an immortalized breast cancer-associated fibroblast line (Pauley et
al., 2000).
With the understanding that there are several types of cells in the breast,
the Gillies laboratory designed a study to look at genomic expression differences
as a result of exposure to an acidic pHe. Gene expression analyses, using an
Affymetrix GeneChip HG U133 Plus 2.0 Array, were performed for 6 human
breast cell lines grown in 3D rBM overlay cultures at either a neutral or an acidic
pHe. The 6 breast cells are: MCF10A, MCF10.DCIS, SUM 102, SUM 225, WS12Ti, and N1ME. Results from the microarray study were used to identify a
transcriptional signaling pathway response to acidic pHe that may influence DCIS
progression.
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Results and Discussion

4.2.1 Microarray data collection
Although more thoroughly described in Methods Chapter 2, for this study
six cell lines were grown in 3D rBM overlay cultures for 8 days in their respective
growth media and then changed to media buffered to maintain a pH of either 6.8
or 7.4 for 3 days. The cells were harvested and total RNA isolated. The RNA
was analyzed using an Affymetrix GeneChip Array. From the initial data analysis
an excel file {acidic_response1(1).xls} was generated with results for 29,486
genes that were altered at the acidic pHe among the 6 cell lines (provided as a
supplemental file). Data collected includes gene information (Entrez ID, symbol,
description, unigene IDs, and probe ID(s) for each of these genes), a fluorescent
output signal, fold change, and p-value for each gene significantly changed at
slightly acidic as compared to neutral pH for each of the individual cell lines as
well as an average of all six cell lines.
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4.2.2 Parsing microarray data
From this initial data collection, we identified ≥500 genes whose
expression was altered in a minimum of four out of the six cell lines and had an
average fold change of at least 1.2 between the cells exposed to a pHe of 6.8
and 7.4. Listed in Table 4.1 is a small subset of genes that are upregulated and
of interest to ongoing projects in the Sloane and Gillies laboratories.

Dr.

Wojtkowiak of the Gillies laboratory followed up on the upregulation of ATG5,
which is an autophagic protein that assists in maturation of developing
autophagophores. Wojtkowiak et al. (2012) hypothesized that autophagy has a
role in mediating survival responses in cells conditioned for survival and growth
at pH. The elevation of cathepsin B in 4 of the 6 cell lines is in agreement with
proteomic analyses that found elevated cathepsin B and its cell surface binding
partner annexin II in ductal carcinoma in situ breast tissue as compared to
matched controls (Wulfkuhle et al., 2002). Those results provided a rationale for
my studies on cathepsin B and proteolysis at an acidic pHe, which I describe
further in chapter 3.
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Gene
Symbol

Gene Description

Score out
Average
of 6 cell
FC
lines

NEBL

Nebulette

7.09

4

DLC1

Deleted in liver cancer 1

5.76

5

DCAKD

Dephospho-CoA kinase

4.01

4

3.14

4

PPP1R1B Protein phosphatase 1
ANXA11

Annexin A11

2.46

4

IL32

Interleukin 32

2.26

4

S100P

S100 calcium binding protein P

1.93

5

TIMP3

Tissue inhibitor of
metalloproteinase 3
ATG5 autophagy related 5

1.61

4

1.58

4

1.52

5

ATG5

ARHGAP5 Rho GTPase activating protein 5
CTSB

Cathepsin B

1.43

5

SOD2

Superoxide dismutase 2

1.36

4

1.27

4

ALDH1A3 Aldehyde dehydrogenase 1

Table 4.1. Selected genes increased in expression at pHe 6.8 in at least 4
out of 6 cell lines. Genes are shown here in order of fold change from > 3.0
(cyan), >1.5 (light blue), and > 1.2.

Table 4.1.
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4.2.3 Commonly upregulated genes
Using the excel sheet {acidic_response1(1).xls} I performed a systematic
search for genes upregulated 1.5 fold or greater at the acidic pH for each cell
line. There were no commonly upregulated genes among the 6 cell lines at this
cutoff value. There were 6 common Entrez gene IDs among the 3 DCIS cell
lines, but only 4 corresponded to validated genes. Those genes are interferoninduced protein 35 (IFI35), endoplasmic reticulum aminopeptidase 1 (ERAP1),
oliogadenylate synthase 1 (OAS1), and a catalytic subunit of DNA polymerase 1
(POL1).

To determine if these genes were connected, I used Genomatix

Pathway System software. The pathway system module will statistically
associate user-input data with verified regulatory pathway information based on
literature for genes, proteins and their interactions. The analysis was performed
and several biological processes (Table 4.2), molecular functions (Table 4.3),
and 3 diseases (Table 4.4) were found.
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GO-Term

#
P-value Genes
(total)

List of observed
genes

immune response

5.11E-04

736

IFI35, ERAP1, OAS1

immune system process

1.64E-03

1094

IFI35, ERAP1, OAS1

antigen processing and
presentation of endogenous
peptide antigen via MHC
class I

1.67E-03

6

ERAP1

antigen processing and
presentation of endogenous
peptide antigen

1.67E-03

6

ERAP1

antigen processing and
presentation of endogenous
antigen

2.23E-03

8

ERAP1

response to other organism

3.91E-03

373

IFI35, ERAP1

response to stimulus

4.49E-03

3713

IFI35, ERAP1,
OAS1, POLI

antigen processing and
presentation of peptide
antigen via MHC class I

5.01E-03

18

ERAP1

response to biotic stimulus

6.10E-03

468

IFI35, ERAP1

antigen processing and
presentation of peptide
antigen

7.23E-03

26

ERAP1

membrane protein
ectodomain proteolysis

7.51E-03

27

ERAP1

membrane protein proteolysis 8.90E-03

32

ERAP1

Table 4.2. Top Gene Ontology biological processes, as determined by
Genomatix, for the commonly elevated genes among the three DCIS cell
lines at pHe 6.8. Genes with a minimum average fold change > 1.5 were
considered.

Table 4.2.
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GO-Term

P-value

# Genes
(total)

List of observed
genes

nucleotidyltransferase activity

3.56E-04

120

OAS1, POLI

interleukin-6 receptor binding

1.55E-03

6

ERAP1

interleukin-1 receptor binding

2.85E-03

11

ERAP1

aminopeptidase activity

8.01E-03

31

ERAP1

DNA-directed DNA polymerase
8.27E-03
activity

32

POLI

DNA polymerase activity

9.55E-03

37

POLI

metalloexopeptidase activity

9.81E-03

38

ERAP1

Table 4.3.
Table 4.3. Top Gene Ontology molecular functions, as determined by
Genomatix, for the commonly elevated genes among the three DCIS cell
lines at pHe 6.8. Genes with a minimum average fold change > 1.5 were
considered.
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# Genes
List of observed genes
(total)

MeSH-Term

P-value

Carcinoma, Basal Cell

3.72E-04

710

IFI35, ERAP1, OAS1

Neoplasms, Basal Cell

4.44E-04

754

IFI35, ERAP1, OAS1

Bowen's Disease

7.75E-04

177

IFI35, OAS1

Table 4.4
Table 4.4 Significant diseases, as determined by Genomatix, for the
commonly elevated genes among the three DCIS cell lines at pHe 6.8.
Genes with a minimum average fold change > 1.5 were considered.
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Genomatix like other pathway analysis software (Ingenuity IPA, or

GeneGo) uses published literature systematically mined by computer and hand
(human) curations to establish a biological context for genes and proteins.
Because of the vast differences in terminology across fields and disciplines,
Open Biological and Biomedical Ontologies, a website foundry, has established
organizational systems for classification of biomedical terms (Smith et al., 2007).
Gene Ontology is one of these, which focuses on the vocabulary of genes, their
products and annotations. Gene Ontology classifies the genes into 3 domains:
1)

Cellular component---where the products are located in relation to

the cell as a whole, organelles of a eukaryotic cell, or protein complex
2)

Molecular function---the gene product function or activity (e.g.,

binding, or transporter activity) or role played in a more specific cellular
activity (e.g., interleukin-6 receptor binding),
3)

Biological process---series of events of at least one or more distinct

steps or a succession of molecular functions typically with a start and
end, but does not discriminate dynamics or dependencies that would be
encompassed in a pathway (Ashburner et al., 2000).
Genomatix pathway analysis software used Gene Ontology terms to classify my
list of genes that were commonly elevated at an acidic pHe to both biological
processes (Table 4.2) and their molecular functions (Table 4.3). Similarly the
software used Medical Subject Headings (MeSH) (Rogers, 1963) as the classifier
for diseases (Table 4.4).
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Three of the four upregulated genes (ERAP1, IFI35 and OAS1) modulate

immune responses (Table 4.2) and are associated with the MeSH term “basalcell” cancers (Table 4.4). ERAP1 plays a central role in peptide trimming in the
ER, allowing peptides to be loaded into major histocompatibility complex (MHC)
class-1 molecules for self-recognition by the immune system (Chang et al.,
2005). Interestingly, ERAP1 is also required for interleukin 6 receptor (IL-6R)
shedding (Cui et al., 2003). Shedding can lead to signal amplification, prolonged
half-life and allows IL-6 signaling in cells not expressing IL-6R (Jones et al.,
1999; Marin et al., 2002; Peters et al., 1996).

Following activation by IL-6,

downstream signaling leads to activation of
(STAT) family members 1 and 3 (Gerhartz et al., 1996). STAT1 signaling
can increase IFI35 transcription.

IFI35 is a leucine zipper protein that is

translocated from cytoplasmic aggregates into the nucleus following interferon
treatment, but IFI35 does not mediate transcription despite the common
transcription factor motiff (Bange et al., 1994). OAS1 is a member of the 2-5A
synthetase family, which is most well known for mediating the innate immune
response to viral infections following interferon signaling.
The transcript signals from the microarrays original read were additionally
analyzed with 2 separate pathway analysis tools.

The software platforms

perform enrichment analysis to identify relevant canonical pathways, networks,
and Gene Ontology classifications.

The Gillies laboratory used GeneGo

MetaCore pathway analysis software to look for commonalties among all 6 cell
lines and we, with the collaboration of the Systems and Computational Biology
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Core, used Ingenuity Pathway Analysis (IPA) to identify common responses
among the three DCIS cell lines (see below).
4.2.4

Unique rigorous examination using IPA pathway analysis

4.2.4.1

SScore

Instead of using the excel file, I took the data collected from arrays (i.e.,
original CHP, CEL and RPT files) to the Systems and Computational Biology
Core at Karmanos.

We performed an analytical workflow to allow extraction of

high confidence results from the Moffitt-designed single replicate microarrays for
the 6 cell lines. To do this in the absence of true technical replicates, we took
advantage of the 20 pairs of matched probes for each gene on the Affymetrix
chip and used this internal chip data to estimate an error model for the gene
expression differences via SScore (significance score) analysis. "SScore offers
high sensitivity without loss of specificity in detecting differentially expressed
genes. The SScore produces accurate results even when few or no replicates
are available” (Kennedy et al., 2006). SScore is designed to compare gene
expression of Affymetrix genechips using probe pair signal intensities that take
into account background noise levels in order to determine significant differences
in gene expression. The SScore analysis outputs a standard normal distribution
centered around zero or no change in expression and thus p-values can easily
be determined. In our case the SScore was used to determine if the probe pairs
average had a statistically significant chance of being "real changes" in terms of
the chip hybridization observed at the acidic as compared to the neutral pHe.
Three SScore values were considered: 3, 2.5 and 1.96, each corresponding with
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a predictive percentage of real change of 99.7%, 99%, and 95%, respectively.
The most stringent SScore of 3 (two-tailed, p-value=0.003) was chosen as an
appropriate cut-off for selection of genes for further analysis. The numbers of
probes and genes in all six cell lines that were identified with this SScore cut-off
are displayed in Table 4.5.

Cell Lines

Probe Count at
SScore of 3

RefSeq Genes
Represented

MCF-10A

652

440

MCF10.DCIS

549

320

SUM 102

969

713

SUM 225

618

474

N1ME

972

664

WS-12Ti

982

689

Table 4.5. Probes and corresponding genes changed at pHe 6.8 in each of
six cell lines. Probes represent ones changed, using an SScore of three.

Table 4.5
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4.2.4.2

Genespring quality controls

The Systems and Computational Biology Core simultaneously matched
probe data from Affymetrix .CEL files to an Entrez ID in GeneSpring and
normalized the data to internal controls.

GeneSpring is a highly specialized

bioinformatics software program that is able to associate the Affymetrix probes
with genes as well as perform a quality control analysis.

The output of the

GeneSpring analysis included box and whisker plots (Figure 4.1) and profile plots
(Figure 4.2). An applied table / excel file was created to provide gene and probe
identifiers and used to generate the probe count histograms for significant Entrez
genes at the SScore cutoff of 3 (Figure 4.3).

Upon confirming quality data

(Figures 4.1 and 4.2), the significantly changed Entrez gene IDs numbers shown
in Figure 4.3 were further analyzed to determine the fold change.

The fold

change value for each significant gene compares the values at the experimental
acidic pH condition (pHe 6.8) to those at the control neutral pH condition (pHe
7.4).
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Normalized Intensity Values

Figure 4.1.2

Figure 4.1.2
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Normalized Intensity Values
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Figure 4.1. GeneSpring quality control for intensity of fluorescent signals.
Graphs, for the indicated number of probes, indicate the minimum (bottom of the
lower whisker), the first quartile (lower border of the box), the median (line
through the box), the third quartile (upper border of the box), and the maximum
(top of the upper whisker) of the distribution of normalized fluorescent signals.
Most signals are within 2 standard deviations (outliers are red bars) and are
comparable within a single cell line at either of the two pHe’s: 7.4 or 6.8.
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Figure 4.2.2
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Figure 4.2. Profile plots for intensity of fluorescent signals indicative of
changes in transcripts. Normalized fluorescent signals of probes for each cell
line grown in 3D rBM overlay cultures at either pH 7.4 (left) or 6.8 (right) are
illustrated. Decreased signals are shown in red, unchanged in yellow, and
increased in blue at the acidic pHe, using a paired expression analysis.
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Figure 4.3. Quality control histograms illustrating the number (1-6) of
significantly changed probes at pH 6.8 to a single RefSeq gene ID.
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4.2.4.3

Commonalities among the three DCIS cell lines

The goal of our studies is to identify molecular mechanisms for acidmediated invasion using an unbiased method with a focus on the response of
pre-invasive DCIS cells to acidic pHe. We explored the commonalities among
the three human DCIS cell lines upon exposure to acidic pH. We chose to use
the web-based program BioVenn to compare and visualize the overlap in
significant gene expression lists because BioVenn allows visualization of areaproportional Venn diagrams (Hulsen et al., 2008). The Entrez gene IDs for the
genes significantly changed at the acidic pHe for each of the three DCIS cell
lines were entered into BioVenn. The output Venn diagram has three circles with
each circle corresponding to the total number of significantly changed genes for a
single DCIS cell line (Figure 4.4). The overlapping area between two circles
represents the genes commonly changed in the two cell lines, whereas the
central node of the Venn diagram represents genes commonly changed in all
three cell lines. The size of the circles and overlapping areas are proportional;
for example, the largest circle corresponds to the largest number of significantly
changed genes. The numbers indicate significantly changed genes. There are
only 7 common genes among all three DCIS cell lines (Figure 4.4). The 7 Entrez
IDs correspond with te following genes: ARG2 (Arginase, type II), ATP11B
(ATPase, class VI, type 11B), IFI35 (interferon-induced protein 35), MTHFD1L
(methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like), PBX2
(pre-B-cell leukemia homeobox 2), S100P (S100 calcium binding protein P) and
STAT1 (signal transducer and activator of transcription 1).
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Figure 4.4. Genes significantly changed at pHe 6.8 in three human DCIS
4.4. image depicts the proportional input of significantly changed
cellFigure
lines. BioVenn
genes. The 102 genes in regions of overlap among two or more DCIS cell lines
were used for subsequent IPA studies. The seven genes changed in common
are ARG2, ATP11B, IFI35, MTHFDIL PBX2, S100P, and STAT1.
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4.2.4.4 IPA core analysis
To perform a proper pathway analysis the commonalities in two of three
cell lines were analyzed for the 102 genes determined to be the DCIS response
to acidic pH (Figure 4.4). The 102 Entrez IDs identified in BioVenn were put into
IPA and annotated to generate gene information. Subsequently, these lists were
run through an R-program “Make_FC_file.R” (provided as a supplemental file) to
put together the Entrez ID and gene information with the fold change values for
each gene of interest for each of the individual three DCIS cell lines. In addition I
compiled an average fold change value for the significantly changed 102 genes
in the DCIS cells at acidic pHe. This information is compiled in an excel file
“propeller for IPASig3” (provided as a supplemental file). I used the average fold
change values for the 102 significantly changed genes at the acidic pHe for two
or more DCIS cell lines in IPA core analysis.

The average change values

accurately represent the significant changes in each of the individual DCIS cell
lines (i.e., the genes changed in a common direction and were close to the
average values).
The IPA core analysis is a powerful software that uses algorithms for datamining of published research with expert hand-curation by professionals to
integrate molecular and chemical interactions.

IPA analysis of our data on

response to acidic pHe revealed that the most significant pathway was interferon
signaling in which the transcription factor STAT1 and several of its downstream
targets were upregulated (Figures 4.5 and 4.6 and Table 4.6). Collectively, our
results suggest an important role for STAT1 signaling in response to acidic pHe
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in three human DCIS cell lines of different origins. This has led us to hypothesize
that the interferon signaling pathway is upregulated under acidic growth
conditions and may be important for survival and selection of cancer cells that
are invasive in the acidic microenvironment surrounding solid tumors.

This

pathway was absent in normal cells exposed to acidic pHe, such as N1ME
myoepithelial cells and MFC-10A analyzed by the same methods (SScore 3 and
FC determination) (Figure 4.7).
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Figure 4.5. Top canonical pathways, as determined by IPA core analysis,
using the 102 genes identified in Figure 4.4. The most significant pathway is
interferon signaling in which 8 out of 36 genes in the pathway were significantly
altered at the acidic pHe.
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Extracellular
Symbol
IFI35

FC
1.854

IFIT1

2.106

IFITM1

1.890

IRF9

1.433

MX1

1.917

OAS1

1.605

PSMB8
STAT1

1.334
1.271

Nucleus

Figure 4.6. Interferon signaling pathway illustrating that in response to an
acidic microenvironment STAT1 drives the transcriptional regulation of
downstream target genes. In this diagram, the canonical interferon signaling
pathway is overlaid with the average significant fold-change value of the 102
Figure
4.6 All significantly changed genes (8) in the pathway (36 total)
genes
identified.
exhibit elevated transcription at pHe 6.8. The darker the shade of red the greater
the upregulation of expression: actual values are given in the insert to the left.
Green would depict downregulation of expression at pHe 6.8; however, there
were no genes in the pathway that are downregulated.
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Seven Upregulated Downstream Targets
IFITM1
interferon induced transmembrane protein 1

Average fold
change
2.313

PSMB8

proteasome subunit, beta type, 8

1.423

IFI35

interferon-induced protein 35

1.854

IRF9

interferon regulatory factor 9

1.459

IFIT1

interferon-induced protein with
tetratricopeptide repeats 1

2.513

OAS1

2',5'-oligoadenylate synthetase 1

1.705

MX1

myxovirus resistance 1

2.254

Table 4.6. Seven upregulated downstream target genes of STAT1-driven
Table 4.6.
interferon signaling. Gene symbols, names and average fold change values
are identified.
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Figure 4.7.
Interferon signaling pathway illustrating that in nontransformed cells STAT1 does not drive the transcriptional regulation of
downstream target genes in response to an acidic microenvironment. In
this diagram, the canonical interferon signaling pathway overlaid with color to
indicate the significant fold change values of the diploid MCF10A (A) and
myoepithelial N1ME (B) cells identified at an SScore of three (see Table 4.5).
The darker the shade of red the greater the upregulation of expression; green
depicts downregulation of expression at pHe 6.8.
Although STAT1 is
upregulated in MCF-10A acini, there is little indication of activation as indicated
by the absence of changes in downstream target genes.
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STAT1, or Signal Transducer and Activator of Transcription 1, is a well-

studied transcription factor that mediates stress responses that regulate cell
growth, differentiation, apoptosis and immune functions. There is debate in the
field as to whether its role in cancer is as a suppressor or a promoter.
Traditionally, STAT1 is characterized as a tumor suppressor due to its role in
restraining growth and increasing cellular apoptosis (Khodarev et al., 2010;
Pitroda et al., 2009). Consistent with STAT1 being a tumor suppressor is that it
is down-regulated in human squamous cell head and neck cancer and plays a
protective role against development of carcinogen-induced and spontaneous
cancer, which is absent in STAT1 deficient mice (Efimova et al., 2009;
Shankaran et al., 2001).

Recently, new functions are emerging for elevated

STAT1: 1) resistance to cancer therapies such as ionizing radiation (Amundson
et al., 2004) and chemotherapy (Khodarev et al., 2009; Thomas et al., 2004); 2)
transcriptional regulation of proteins involved in glycolysis (Warning et al., 2011);
and 3) up-regulation of IL-6 and IL-8 (Efimova et al., 2009). IL-6 and IL-8 are
both cytokines of interest in our laboratory as they are associated with increased
invasiveness of breast cancer (Mohamed et al., 2010).

We have found that

STAT1 is upregulated in response to acidic pHe, whereas others have observed
STAT1 upregulation in response to hypoxia (Lee et al., 2006). Hypoxia and pHe
are common conditions in solid tumors and are very difficult to study
independently in vivo.

STAT1 has been shown to have a role in altering

glycolytic pathways (Pitroda et al., 2009), suggesting an important role for this
transcription factor in the development of an acidic extracellular pH.
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mediates stress responses regulating cell growth, differentiation, apoptosis, and
immune functions, but its role in cancer is still not clearly defined. Our finding
that STAT1 and downstream factors are upregulated in DCIS cells in response to
acidic pHe indicates that STAT1 warrants further investigation as a tumor
enhancer in pre-invasive carcinoma and may lend credence to targeting these
pathways earlier in cancer progression for therapeutic benefit.
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SUMMARY AND FUTURE DIRECTIONS
The purpose of this dissertation work was to examine the effects of an
acidic tumor microenvironment (acidic pHe) on proteolysis and gene expression
in breast carcinoma. Our study builds on strong previous reports that support the
hypothesis that the acidic environment generated by tumors is integral to their
ability to invade, i.e., the acid-mediated invasion hypothesis (Chapter 1.4).

For

our studies we used 3D rBM overlay cultures and examined the effects on
proteolysis and gene expression of the cells at acidic (6.8) compared to a neutral
(7.4) pHe.

The pHe of 6.8 was chosen as our test condition because it is

representative of the average pHe in human breast carcinomas. We were able
to show that maintaining invasive carcinoma cells in 3D rBM overlay cultures at
an acidic pHe resulted in an increase in the degradation of the basement
membrane protein, type IV collagen, and demonstrate that this increase was due
in part to an elevation in the levels of active cysteine cathepsins adjacent to the
outer surface of the tumor cells (Chapter 3). We also did a microarray study on
breast cell lines cultured in 3D rBM overlay cultures at an acidic pHe. The results
of the bioinformatic analyses led to the hypothesis that STAT1-signaling has an
important oncogenic role in DCIS cells exposed to an acidic pHe (Chapter 4).
The new insights derived from these analyses lay the groundwork for future
experiments.
The studies described in Chapter 3 used GB123, an ABP that is selective
for a number of cysteine cathepsins, namely cathepsins B, L, and S. We were
able to identify and pull-out ABP-bound cathepsin B and cathepsin L from MDA	
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MB-231 cell lysates.

By culturing MDA-MB-231 and two other invasive

carcinoma cells in 3D rBM overlay cultures at acidic pHe, we demonstrated both
a dramatic increase in general proteolysis that could be reduced by a highly
selective cathepsin B inhibitor (i.e., CA074) and an increase in the pericellular
localization of the active enzyme using GB123. The increased proteolysis at the
acidic pHe and proteolysis at the neutral pHe was only partially reduced by
inhibition of cathepsin B.

Therefore our study should be expanded because

additional proteases must participate in the proteolysis.

There are currently

ABPs available for other cysteine proteases such as legumain (Edgington et al.,
2013) as well as other proteolytic families such as serine proteases (Liu et al.,
1999) and MMPs (Keow et al., 2012). By using inhibitors that are selective for
different proteases and synthetic substrates for a variety of proteases, one
should be able to gain a comprehensive look at how the acidic pHe influences
the activity of proteases leading invasion and metastasis.

Additionally, by

moving to quenched ABPs that do not fluoresce before interacting with the
enzyme we could reduce the time required for removal of unbound probes
allowing analysis of more samples (Chapter 2.4).
The studies could also be expanded to include multiple cell types in the
MAME cultures because we have shown that different cell types present in the
tumor microenvironment can modulate the breast cancer proteolysis.

For

example, tumor associated fibroblasts in co-culture with breast or colon cancer
cells increase degradation of DQ-collagen IV by 3-15 fold (Sameni et al., 2009;
Sameni et al., 2003) and myoepithelial cells are able to reduce the degradation
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(Sameni and Sloane, in preparation). Another microenvironmental component
closely related to pHe is oxygen availability and experimental protocols could be
designed to look at the degradation and or presence of proteases under acidic
and hypoxic conditions.
To confirm the findings described in Chapter 4 it will be necessary to
validate the microarray results. Validation studies have been started by looking
for STAT1 and the downstream transcriptional targets through quantitative RTPCR of the three available cell lines of human DCIS cultured the same as they
were for the microarray. After validation at the transcript level, expression of
proteins can be verified through western blotting and/or by quantitative proteomic
techniques.

We, in collaboration with the Gillies laboratory, have assembled a

list of proteins of interest including the STAT1 canonical pathway members that
will be analyzed by liquid chromatography-multiple reaction monitoring-mass
spectrometry (LC-MRM-MS). Those results should then be evaluated for
commonalities and discordances with the microarray data using BioVenn and
pathway analysis software such as IPA. We expect that such additional analyses
will confirm the original microarray data, which suggests that an acidic pHe
induces up-regulation of the STAT1 signaling pathway in DCIS cells.
We showed that carcinoma cell lines grown in 3D rBM overlay cultures
survive and proliferate at an acidic pHe, thus exhibiting an acid-resistant
phenotype (Figure 3.4).

We predict that in vivo DCIS lesions acquire an acid-

resistant phenotype during the intermittent hypoxic conditions found during
cancer progression (Figure 1.4); however the characterization of acid-resistance
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has yet to be performed in human DCIS cells in vitro. We anticipate mixed
results with respect to acid-resistance among the DCIS cell lines due to their
different origins, which were described in Chapter 4.1. Preliminary findings of
acid-resistance, using an MTT assay, have confirmed that there are differences,
but further studies using proliferation and live-dead assays should provide
additional information.

The current study might have been confounded by

toxicities due to the acidic pHe; however, visual observation (J. Dosescu) did not
support toxic effects.

If the acid-resistance or lack-there-of is of concern,

comparisons with DCIS cells that have been uniformly adapted to an acidic-pHe
(a method that has been described previously (Wojtkowiak et al., 2012)) or
comparisons with primary cultures of human DCIS could be undertaken. Since
our study began costs of running microarrays have gone down, and it may be
worthwhile to repeat the microarray to make these comparisons.
Molecular responses that result in both increased proteolysis and STAT1
signaling begin by sensing and relaying the detection of acidic pHe. To our
knowledge the expression of ASICs in breast epithelium and in breast cancer has
yet to be characterized. Macrophages express ASICs 1 and 3 and respond to an
acidic pHe by increasing endocytosis (e.g., for antigen presentation) and exocytic
secretion of cytokines (Kong et al., 2013). Previous reports by our laboratory and
others have shown an important role for macrophages in the secretion of
cysteine cathepsins in cancer (Gocheva et al., 2010; Mohamed et al., 2010;
Vasiljeva et al., 2006). Others have reported expression of ASICs in gliomas that
parallel their invasiveness (Berdiev et al., 2003). On the other hand, increases in
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expression and activity of cathepsin B in gliomas correspond to increased
invasiveness (Rempel et al., 1994). A direct link between ASICs and regulation
of cysteine cathepsin secretion needs to be examined.

There may also be

interactions between STAT1 signaling and ASICs as both activate PI3K signaling
(Brown and Wagner, 2012; Chu et al., 2011; Duan et al., 2012; Fruhbeck, 2006).
STAT1

supports

oncogenic

growth

and

up-regulates

genes

driving

glycolysis/gluconeogenesis suggesting a role in mediating the high glycolytic
phenotype of tumors (i.e., Warburg effect) (Pitroda et al., 2009) and thus the
development of the acidic pHe observed in solid tumors. Therefore, both STAT1
and ASIC signaling pathways warrant further investigation independently as well
as in regard to possible cross-talk between the two pathways in the progression
from DCIS to invasive carcinoma.
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ABSTRACT
ACIDIC PERICELLULAR PH: EFFECTS ON PROTEOLYSIS AND GENE
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Among the non-cellular microenvironmental factors that contribute to
malignancy of solid tumors is an acidic peritumoral pH. The first objective was to
determine if an acidic extracellular pH observed in vivo (i.e., pHe 6.8) affects the
activity of proteases, such as cathepsin B, that contribute to degradation of
collagen IV by tumor cells when grown in biologically relevant three-dimensional
cultures.

At pHe 6.8 there were increases in pericellular active cysteine

cathepsins and in degradation of DQ-collagen IV, which was partially blocked by
a cathepsin B inhibitor. Imaging probes for active cysteine cathepsins localized
to tumors in vivo. The amount of bound probe decreased in tumors in
bicarbonate-treated mice, a treatment previously shown to increase peritumoral
pHe and reduce local invasion of the tumors. Our results are consistent with the
acid-mediated invasion hypothesis and with a role for cathepsin B in promoting
degradation of a basement membrane protein substrate, i.e. type IV collagen, in
an acidic peritumoral environment.

The second objective was to use a

microarray approach to identify significantly altered genes that may be of
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importance in the response to acidic pH in ductal carcinoma in situ (DCIS). We
have found that STAT1-directed signaling is up-regulated in response to acidic
pH extracellularly. Its role in altering glycolytic pathways suggests an important
role for this transcription factor in the development of an acidic extracellular pH.
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